KERALA MEDICAL SERVICES CORPORATION LIMITED

(A Government of Kerala Undertaking)

Thycaud P.O, Thiruvananthapuram, KERALA 695 014

INVITATION OF EXPRESSION OF INTEREST

for

EMPANELMENT OF DRUGS TESTING LABORATORIES

EOI No: KMSCL/QC/EOI/2019/01 dated 15.11.2018

Name of EOI Responder:

Address:

Last date and time for the receipt of EOI Response: **12.12.2018. 02.30pm**

For details;

www.kmscl.kerala.gov.in

Email: **kmsclqc@gmail.com**

Table of Contents

SECTION I
INVITATION OF EXPRESSION OF INTEREST

1.1 The Kerala Medical Services Corporation Limited - hereinafter mentioned in this document as KMSCL or the Corporation - is a fully owned Government of Kerala company set up in 2007 for providing services to the various health care institutions under the Department of Family Welfare and Health. One of the key objectives of the KMSCL is to act as the central procurement agency for all essential drugs, other consumables and equipments for all health care institutions under the above said Department.

1.2 The Corporation invites applications in the form of Expression of Interest - EOI in short- for Empanelment of Drugs Testing Laboratories for the Analysis of Drugs, Medical Devices, Supplies, Surgical Sutures etc more specifically mentioned in Appendix for a period of two years from the Date of Acceptance. The Managing Director of the Corporation is the Expression of Interest Inviting Authority for this purpose.

1.3 Laboratories which are willing to undertake complete testing and analysis of the drugs, other medical supplies and consumables at the rates prescribed in the Appendix I-A and offer rates for complete testing of the items in Appendix I-B and willing to accept the terms and conditions as prescribed under the EOI document are eligible to be selected as the "Empanelled Drugs Testing Laboratory of KMSCL".

1.4 The rates specified for the test/ analysis in this document are the final rates, that include all costs of chemicals, reagents, other supplies and consumables, capital investments in equipments, infrastructure, and all overheads for performing tests/ analysis as per the standards applicable analysis and for furnishing test reports together with all relevant protocols to KMSCL. The offerers shall be willing to undertake the tests/analysis subscribing to terms and conditions of this EOI document at these pre-fixed rates.

1.5 Performance of the tests/analysis strictly in accordance with the official/ recognized parameters of standards and delivery of test/ analysis reports in time and consistency of the analysis results are the most important factors to be adhered to by the Empanelled Laboratories.

1.6 The period of contract shall be two years from the date specified in the agreement to be executed for the purpose of the contract. The EOI Offerer shall give firmness of the rate prescribed and agreed upon for a period of two years from the date of agreement.

SECTION II

EOI SCHEDULE

2.1 **Important details of the EOI:**

1.	*EOI No.*	**KMSCL/QC/EOI/2019/01**
2.	*Cost of EOI Document*	**Rs.1000/-**
3.	*Earnest Money Deposit*	Rs.25,000/- (refundable)
4.	*Form of Earnest Money Deposit*	Demand Draft
5.	*Validity of EMD*	180 days from the date of opening of technical document
6.	*Performance Security Deposit*	Rs.50,000/-
7.	*Validity of Performance Security deposit*	30 months from the date of execution of agreement

2.2 **Important Dates:**

Sl.No	Particulars	Date and time	Venue
1.	*Date and time of commencement of sale of EOI document*	**15.11.2018 2.30 pm**	**Head Office, KMSCL.**
2.	*Date and time of Pre- offer meeting*	**27.11.2018 11 am**	
3.	*Last date and time of receipt of offers*	**12.12.2018 2.30 pm**	
4.	*Date and time of opening of the offers*	**12.12.2018 3.00 pm**	

SECTION – III
SPECIFIC CONDITIONS OF EOI

3.1 **Time Limits:**

The Empanelled Drug testing Laboratories shall furnish test reports at the Corporation with in the time limit specified below:			
Category	**Permitted from the date of receipt of sample**	**Penalty for delayed reporting**	
		Step -I	**Step –II***
All non-sterile preparations	15 days	@ 0.5% per day of the delayed reporting upto a max of 15% (30 days) Note-from 16th to 45th day.	@ 1% /day of the delayed reporting upto a max of 45% (30 days) Note- from 46th to 75th day
All sterile preparations	30 days	@ 0.5% /day of the delayed reporting upto a max of 15% (30 days) Note -from 31st to 60th day	@ 1% /day of the delayed reporting upto a max of 45% (30 days) Note-from 61st to 90th day

***Note*: 1.** *The time period shall be calculated from the date noted in the proof of delivery (POD) submitted by the couriers, which shall be binding on the empanelled lab.*

2. *if further delay occur in submitting of that particular test report for more than the following days* that particular test reports will be rejected and action will be taken as per clause 4.9.15.*

** i. Non- Sterile Preparations :- 75 days (ie: 15+30+30)*

**ii. Sterile Preparations:- 90days (ie: 30+30+30)*

3.1.1 If any of the test reports are cancelled/rejected due to delay, the expenditure and other losses sustained in the process, shall be recovered from the Security Deposit or performance guarantee or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier.

3.2 **Prequalification Criteria:**

3.2.1 The Laboratory presenting the EOI (Offerer) shall have valid Approval under the Drugs and Cosmetics Rules, 1945, valid Good Laboratory Practices (GLP) certificate issued by the competent authority under the Drugs and Cosmetics Rules and with valid NABL accreditation. No EOI shall be presented in respect of any drug or any other item in respect of which such approval/ certificate/accreditation is not possessed by the Offerer.

3.2.2 The Offerer should have standing in the field of testing and analysis of drugs/ consumables & other supplies in respect of which the EOI has been made for the last three years.

3.2.3 The Offerer shall have an average annual turnover of not less than Rs. 25 lakhs (Twenty five lakhs) for the last three consecutive years .i.e., 2015-2016, 2016-2017 and 2017-2018.

3.2.4 The Offerer shall be a stand-alone laboratory i.e independent and not an in-house facility part of a manufacturing unit.

3.2.5 The Offerer should have undertaken analysis of drugs and supplies of similar nature for at least three Government departments/ institutions / reputed manufacturers of drugs & supplies during the last three years.

3.2.6 The Offerer should be one located anywhere in India and should not have been blacklisted by KMSCL during the period of blacklisting or blacklisted/ debarred by any other State / Central Government's organization or one whose approval had been suspended or revoked partially or in full by any statutory authority during the period of blacklisting.

3.2.7. The facilities availed/ offered for test/ analysis of drugs and other items shall be own and located in the premises in respect of which the EOI is made. Performance of tests/analysis partly in one place and partly in another place or fully in a place other than the one in respect of which the EOI is made will not be acceptable.

SECTION-IV

GENERAL CONDITIONS OF CONTRACT

4.1 EOI Document

4.1.1 The terms and conditions governing the Empanelment of laboratories are contained in this "EOI Document". The document can be downloaded from website **www.kmscl.kerala.gov.in.**

4.1.2 Failure to furnish any information/ document as required in this EOI document and submission of an offer not substantially responsive to it in every respect shall be at the Offerer's risk and would result in the rejection of the offer, without any notice.

4.1.3 It is mandatory to provide a check list as per Annexure I as the facing sheet for the EOI offer submitted so as to enable the Corporation to prima facie verify the compliance of submission of requisite documents at the time of opening of EOI. Failure to furnish the check list would make the offer deemed as non-responsive and open for summary rejection.

4.1.4 Language of EOI and other communications and signatories thereof: - The EOI submitted, all documents accompanying it presented thereof and all communications between the Offerer and the EOI Inviting Authority shall be in English language. Supporting documents in originals or copies as the case may be, issued by a statutory authority or court and furnished by the Offerer for the purposes of this EOI or for any purpose after empanelment, may in any other Indian language provided they are accompanied authenticated accurate translation of the relevant passages in the English language in which case, for purposes of interpretation of the offers, the English translation shall govern. Any communication from the Corporation made by an officer of the Corporation not below the rank of Quality Control Manager on behalf of the Managing Director shall be deemed as a communication by the EOI Inviting Authority and any communication/ correspondences made or any paper signed by an Authorized Signatory or (Specific) Power of Attorney (POA) Holder for the purposes of this EOI shall be deemed as communication/ correspondence made by the Offerer provided such POA has been presented along with the EOI in such manner as specified.

4.1.5 The EOI and accompanying documents once submitted shall not be altered in manner and should not have any scope of ambiguity, cutting, pasting, overwriting, masking, alteration etc. Modification of the offer, of the nature and to the extent provided in this document prior to the time and date set for

submission will, however, be entertained. Any overwriting / cutting/ correction otherwise of inadvertent error in the EOI made before its presentation it must be one authenticated with signature of the Offerer in full and such modifications as above that are not duly authenticated would necessitate summary rejection of the EOI. No such correction or modification as above in the accompanying document will be considered and documents with corrections would make the EOI defective/ non-responsive.

4.1.6 The documentary evidences submitted along with the EOI shall be produced duly attested by the Offerer on every page and serially numbered.

4.1.7 A copy of the complete EOI document duly signed on every page by the Offerer or the authorized representative shall be enclosed as part of the EOI as a proof of having read and accepted the terms and conditions of the EOI document.

4.1.8 The EOI shall be a computer typed one and signed by the Offerer or person(s) duly authorized to bind the Offerer to the Contract with Corporation. The person signing the documents shall have due Power of Attorney made by the Board of Directors/Partnership/Proprietor/Society/ Trust etc in cases where person other than the Managing Director/Managing Partner/ President or Chairman of the Society/ Trust etc or sole Proprietor signs the document. The photo of the person authorized to sign the document shall be affixed to the Power of Attorney with due authentication. Where the Managing Director/Managing Partner or other such person as mentioned above or the sole Proprietor signs the EOI and accompanying documents a notarized document attesting the signature of the person shall be furnished. The Power of Attorney shall be in non-judicial stamp paper duly notarized.

4.1.9 An offer submitted in vague/ ambiguous terms and the like, shall be termed as non-responsive and shall be summarily rejected.

4.1.10 At any time prior to the dead line for submission of the EOI, the EOI Inviting Authority may, for any reason, modify the EOI document by amendment. The amendment will be published in the website of the Corporation and shall be binding all prospective Offerers.

4.1.11 Pre-offer meeting will be held by the Corporation to explain briefly about the requirements as well as the terms and conditions of the EOI document and to get the views of the prospective Offerers, as part of ensuring transparency in the EOI process. Failure to attend the pre-offer meeting will not be a disqualification, but will be a loss of opportunity for the prospective Offerer to understand the EOI terms & conditions. Date of pre-offer meeting is

mentioned in Section II. Filled up EOI will be accepted only after the date of pre offer meeting.

4.1.12 The EOI shall remain firm and valid for two years. An offer for a shorter period shall be rejected by the Corporation as non-responsive.

4.1.13 The EOI shall be sent in sealed envelope by registered post or by courier to the following address:

The Managing Director
Kerala Medical Services Corporation Ltd
Thycaud P.O, Thiruvananthapuram -14.
Kerala– 695014.

Phone No: 0471- 2945646, 2945600
e-mail: kmsclqc@gmail.com

4.1.14 The envelope containing the EOI document is to be super scribed with the title **"EXPRESSION OF INTEREST FOR EMPANELMENT OF DRUGS TESTING LABORATORIES No KMSCL/QC/EOI/2019/01 DATED 15.11.2018 FOR THE YEAR 2019-21"**

4.1.15 EOI sent by telex or fax or email is void. The EOI may be presented in person also in sealed envelope, addressed and super scribed as above before the time and date specified.

4.1.16 If the EOI is sent by Registered post or by Courier, it should reach the above office on or before the time and date stipulated in Section II. The Corporation shall not be held liable for the delay in transit.

4.1.17 The Offerer may modify or withdraw its offer, after the EOI submission, provided that written notice of the modification or withdrawal is received by the Corporation before the date of opening of the EOI. The Offerer's modification or withdrawal notice shall be signed by the Offerer or his / her authorized representative, who have signed the original EOI documents. A withdrawal notice may also be sent by fax or email but should necessarily be followed by a signed confirmation copy to be received at the head office of the Corporation before the date of opening of the technical document.

4.2 Earnest Money Deposit (EMD):

4.2.1 The EOI shall be accompanied by the EMD as prescribed. Non-submission of sufficient EMD as mentioned in Section II along with the Technical document shall result in summary rejection of the EOI.

4.2.2 The EMD shall be in the form of demand draft drawn in favour of Managing Director, Kerala Medical Services Corporation Limited, payable at Thiruvananthapuram.

4.2.3 Cheque, Cash payment, Money Order, Fixed deposit, Bank Guarantee etc will not be accepted as EMD and in such cases the EOI offer will be rejected.

4.2.4 Laboratories fully owned by the Government / PSUs and reputed Research & Development Laboratories attached to scientific / research institutions are exempted from remittance of EMD subject to submission of valid documents.

4.2.5 EMD of unsuccessful offerers will be discharged / returned as soon as possible within thirty days after publishing of the final list of successful EOIs by the Corporation.

4.2.6 The successful Offerers' EMD will be discharged upon the Offerer signing the contract and furnishing the performance security. The EMD of the successful Offerer may be adjusted towards the performance security payable.

4.2.7 No interest will be paid for the EMD.

4.2.8 The EMD will be forfeited, if an Offerer;

4.2.8.1 Misrepresents facts or submit false / fake documents during the EOI process.

4.2.8.2 If the Offerer willfully violates any terms and conditions of the EOI documents.

4.2.8.3 If the Offerer withdraws its bid after the opening of EOI document.

4.2.8.4 A successful Offerer fails to sign the contract after issuance of Letter Of Intent.

4.2.8.5. If the EOI offer is rejected on the basis of the non satisfactory inspection report of the Quality control facilities of the firm.

4.3 Empanelment policy:

4.3.1 The list of drugs/supplies for which rates to be finalized for complete Laboratory testing is attached as Appendix I-A & I-B.

i) <u>Appendix I-A</u>

The final rate for testing of samples of each item is pre-fixed and are mentioned in column 7 of Appendix I-A. The Laboratories interested to perform the tests for the items at these rates can make offer for that item in the format specified in Annexure-VII (Consent letter of the Offerer).

ii) <u>Appendix I-B</u>

The rates for testing of the items in this list are not fixed. The Testing Laboratories can offer the rates at which the complete testing of the items are performed and the rate for testing shall be filled by the Offerer in column 5 in

Appendix I-B in the format specified in Annexure-VII (Consent letter of the Offerer)**.** The offered rates shall be inclusive of cost of chemicals, reagents, other consumables, cost and depreciation of value of equipments, infrastructure, labour charges, other overheads and expenses and incidentals to the furnishing of reports. The EOI offering minimum rate for testing will be selected for testing that item.

4.3.2 The EOI Inviting Authority has every right to fix the final testing rate of item comparing with the testing rates for similar products, rates offered by other labs etc.

4.3.3 The EOI Inviting Authority will publish the final testing rate(s) of items in Appendix I-B in the website of the Corporation permitting the other qualified laboratories to match with the final testing rate(s). The Corporation will empanel such laboratories also who have given the consent in writing for testing the items in the final rate(s).

4.4 Contents of the EOI documents:

4.4.1 The EOI must be accompanied by the following documents in the sealed cover submitted. The documents shall be in the format prescribed.

	Documents to be submitted	Format prescribed
1.	Checklist (Annexure –I) for the EOI and the list of documents enclosed, with their page numbers marked. The EOI and the documents should be serially numbered and arranged as per Annexure–I. The page number(s) of each document shall be shown in the checklist.	PDF format in DVD & Hard Copy
2.	The Earnest Money Deposit, IF NOT EXEMPTED, shall be Rs. 25,000/-. The Earnest Money Deposit shall be paid in the form of Demand Draft favouring Managing Director, Kerala Medical Services Corporation Limited, payable at Thiruvananthapuram. IF EXEMPTED as per clause 4.2.4 valid documentary evidence to prove the claim shall be furnished.	Hard Copy

3.	Copy of notarized Documentary evidence for the constitution of the company /concern such as Memorandum and Articles of Association, list of names and addresses of the Directors, along with notary attested copies of Form 32 whenever there is a change of Directors, current Partnership deed (Notary attested copy) etc, Name and address of the Chairman/ President/ Managing Trustee, Secretary etc in the case of societies, trusts etc details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of such Managing Director / Partners / Proprietor/ others responsible for the conduct of business and operation of the laboratory.	PDF format in DVD & Hard Copy
4.	Annual turnover statement (Original) certified by the auditors for last three years i.e., 2015-16, 2016-2017 & 2017-18 as in Annexure-V	PDF format in DVD & Hard Copy
5.	Notary Attested Photocopy of approval for testing of Drugs and the list of drugs approved for testing in the laboratory issued by the Drugs Control Authority and valid renewal with list of approved products for testing.	PDF format in DVD & Hard Copy
6.	Notary Attested Photocopy of valid GLP Certificate issued by the Drugs Control Authority and valid renewal.	PDF format in DVD & Hard Copy
7.	Notary Attested Photocopy of NABL accreditation certificate and its valid renewal.	PDF format in DVD & Hard Copy
8.	Service Tax Clearance Certificate issued by the concerned authority and attested copy of certificate of registration for service tax.	PDF format in DVD & Hard Copy
9.	Notary attested copies of audited Balance Sheet and Profit and Loss account for the last three years i.e. 2015-16, 2016-17 & 2017-18.	PDF format in DVD & Hard

		Copy
10	The list of qualified personnel employed in the laboratory (Employees name, Qualification and experience)	PDF format in DVD & Hard Copy
11.	The list of sophisticated analytical equipments & apparatus available in the laboratory as in Annexure III	PDF format in DVD & Hard Copy
12.	Duly filled performance statement in Annexure IV	PDF format in DVD & Hard Copy
13.	Declaration in the Proforma given in Annexure-VI duly signed and notarized	PDF format in DVD & Hard Copy
14.	Details of Analytical Laboratory in Annexure–II	PDF format in DVD & Hard Copy
15.	Consent letter of the offerer as in Annexure VII, giving the details of the Drug / items offered to be tested in compliance with the EOI conditions and the consent for testing the Drugs / items at the rates offered in Appendix I-A & I-B.	DVD in **.xl** format & Hard Copy
16.	EOI document signed by the offerer in all pages with office seal	Hard Copy
17.	Notary attested copy of PAN.	PDF format in DVD & Hard Copy

4.5 Evaluation of EOI:

4.5.1 The opening of the EOI offer will be done by the Corporation in the presence of the Offerers or their representatives who choose to attend at the respective time and place mentioned in Section II.

4.5.2 In the event of the specified date for EOI submission/opening being declared holiday, the EOI submission/opening shall be at the appointed time and venue on the next working day.

4.5.3 The Offerer shall be responsible for properly super scribing and sealing the envelopes and the Corporation shall not be liable for inadvertent opening of the envelopes before the time appointed for opening of the offers.

4.5.4 The documents submitted as part of the offer shall be scrutinized by Committee constituted by the EOI Inviting Authority.

4.5.5 An EOI, at any stage of the evaluation process or thereafter, in the event of being found concealment or misrepresentation of facts, in respect of the claims of the offer, shall be rejected and is liable to be black listed for a period as decided by the EOI Inviting Authority.

4.5.6 The Corporation may waive any minor infirmity in an offer, which does not constitute a material deviation, provided that the same shall not prejudicially affect the interest of the other Offerers.

4.5.7 No EOI may be withdrawn in the interval after the opening and finalization of the EOIs. Withdrawal of an EOI during this interval will result in the forfeiture of its EMD and black listing of the Offerer for a period of 3 years immediately from the date of such order and the Offerer shall be ineligible to participate in any of the offers / tenders of the Corporation for a period of 3 years.

4.6 Inspection of Testing Facilities of the Laboratory:

4.6.1 Inspection of the testing facilities will be at the discretion of the EOI Inviting Authority. Such inspection may be at any stage before or after acceptance of the offer or Award of Contract/ empanelment.

4.6.2 All the testing facilities in the lab will be subjected to inspection / auditing, irrespective of the items in respect of which the EOI has been made/offered. i.e. if the Offerer has offered testing of only for tablets but is having the testing facilities of Injectables / Liquids / etc. all the sections will be subjected to inspection. The Offerer will have to provide necessary arrangements to conduct the inspection of all the sections and failure to co-operate with the inspection in showing the different facilities, will lead to disqualification. Entry to all the areas of testing including microbiological section of the lab shall be facilitated.

4.6.3 During inspection undue demands, demands beyond the scope of the this EOI etc made by the members of the Inspection team shall be immediately notified to the EOI Inviting Authority by the laboratory by fax/email, so that the disputes could be resolved before the Inspection Team left the laboratory. The recommendations of the Inspection team will not be communicated to the Offerer at their site and shall be published on the later only. A summary of findings without stating the recommendations/ conclusions may, however, be furnished to the laboratory soon after the inspection.

4.6.4 The availability of technical experts, analytical facilities as claimed in the EOI offer along with the compliance of standard operating procedures adapted for each procedure including validation and calibration, shall be evaluated by the team for considering the eligibility of the lab. Claims of holding the valid NABL certification/valid approval/ GLP certificate will not be of any avail, if the procedures prescribed are not followed as per the standard operating procedures or if the available facilities are not in proper conditions or if contraventions of GLP norms are observed at the time of inspection. In the event of failure to facilitate inspection, obstruction to carry out the inspection, non-cooperation during the inspection, failure furnish any record needed for verification etc., the EOI offer will be rejected or agreement will be terminated, as the case may be.

4.6.5 The minimum number of samples that could be tested at a time will be one of the criteria for determining the acceptance/rejection of the lab. The Inspection team shall also verify the capability of the Offerer in fulfilling the requirement of the Corporation.

4.6.6 Copy of one full set of the EOI offer should be made available at the time of inspection.

4.6.7 Originals of all the documents submitted in the EOI offer should be produced for verification by the inspection team. Failure to produce any of the original documents will result in the rejection of the offer.

4.6.8 Key testing areas will be photographed by the inspection team. Denial of permission for photographing will result in the rejection of EOI offer.

4.6.9 Any of the Laboratories during the inspection, found not complying with the requirements, the offer of the firm will be rejected/agreement will be terminated. An inspection fee of Rs. 25,000/- will be deducted from the EMD/SD/any money due to the firm.

4.7 Acceptance / Rejection of offers:

4.7.1 Acceptance /rejection of the EOI offer will be based on the decisions taken on the evaluation of the submitted documents and inspection report from the expert committee.

4.7.2 At any point of time before or after the award of contract, the EOI Inviting Authority reserves the right to cancel or modify the contract in respect all or any of the items of drugs or other consumables in respect of an EOI for breach of the terms and conditions of the EOI or of the agreement thereof.

4.7.3 The EOI Inviting Authority, or his authorized representative(s) has the right to inspect the labs of Offerers, before releasing any samples or at any point of time during the continuance of offer and also has the right to reject the offer or terminate / cancel the contract awarded and or to re-test, based on adverse reports brought out during such inspections. Retesting of samples may also be done by the EOI Inviting Authority at any stage before or during the operation of the contract, to evaluate the performance of the laboratory and the EOI Inviting Authority may initiate deterrent or punitive measures if the evaluation processes or the inspections so indicate or necessitate.

4.8 Award of Contract:

4.8.1 The Corporation will notify the successful Offerer (s) in writing, by registered / speed post or by email that its/ their offer(s) for testing of drug(s)/ other items, which have been selected by the EOI Inviting Authority, has been accepted. This notification is made by issuing a **Letter of Intent** by the EOI Inviting Authority.

4.8.2 The successful Offerer, upon receipt of the Letter of Intent, shall execute an agreement in the format prescribed, in a non-judicial Kerala Stamp paper of value of Rs. 200/- or of such revised value as may be notified by the Government (stamp duty to be paid by the Offerer) within 15 days from the date of the intimation from Corporation that his offer has been accepted. The Specimen format of agreement is available in Annexure-IX.

4.8.3 There will be a performance security deposit amounting to Rs 50,000/- (Rs. Fifty Thousand only) which shall be submitted by the successful Offerer along with the agreement within 15 days from the date of issuance of Letter Of Intent, in the form of Demand Draft drawn in favour of the Managing Director, Kerala Medical Services Corporation Limited payable at Thiruvananthapuram/ Bank Guarantee in the format as given in Annexure VIII for a period of 30 months from the date of execution of the agreement.

4.8.4 If the successful Offerer fails to execute the agreement and / or to deposit the required performance security deposit within the time specified or withdraws his offer after opening of the bid, his award of contract will be cancelled and the Earnest Money Deposit of the firm shall stand forfeited, Corporation will initiate blacklisting process and the laboratory shall also be blacklisted for a period of three years immediately from the date of such order and the Offerer will be ineligible to participate in any of the offers/EOI processes of the Corporation for a period of three years.

4.8.5 The Offerer shall not, at any time, assign, sub-let or make over the contract or the benefit in full or part thereof to any person or persons what so ever.

4.8.6 For infringement of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the EOI Inviting Authority, and the Offerer shall be liable for all losses sustained by the EOI Inviting Authority, in consequence of the termination which may be recovered personally from the Offerer or from his properties, as the case may be.

4.8.7 All notices or communications relating to arising out of this EOI/agreement or any of the terms there of shall be considered duly served on or given to the Offerer if delivered to him or left at the premises, places of business or abode. Any notice or other communication sent by e-mail or by any other electronic mode shall also be deemed to be due service of the notice/ communication.

4.8.8 In the event of any failure/blacklist/default/deviations from the terms and conditions of the EOI or the agreement thereof, of the successful tenderer with or without any quantifiable loss to the EOI Inviting Authority, the amount of the performance security is liable to be forfeited.

4.8.9 The EOI Inviting Authority will release the Performance Security without any interest to the successful Offerer on completion of all contractual obligations.

4.8.10 If the successful Offerer withdraws from the contract during the period of contract, his security deposit will be forfeited, the contract will be terminated, Corporation will initiate blacklisting process and the laboratory will be blacklisted for a period of three years immediately from the date of such order making them ineligible to participate in any of the offers / Tender of the Corporation.

4.9 Testing & Reporting Conditions:

4.9.1 On empanelment and entrustment of the job, the Analytical Laboratory shall furnish the test reports within.

1. 15 days of receipt of the sample in case of all non-sterile Preparations.
2. 30 days of receipt of the sample in the case of sterile preparations.

4.9.2 All the tests mentioned in IP/ BP/ USP/ BIS/In-house test procedure/Drugs & Cosmetics Rules. etc., (as the case may be) should be carried out for each and every sample. The actual test value obtained after analysis should be clearly mentioned in the report figures/& words in the report of test/ analysis. Amendments, Addendum, Corrigendum etc published to the reference monographs shall be taken in to account in the testing parameters time to time.

4.9.3 Mentioning the words, "COMPLIES" or "PASSES" in the result column of the report shall be treated as incomplete report. It is essential to express the value of test results in figures and the value of standard limits.

4.9.4 **Test report should be submitted as per Form 39 of D&C Act and additional details should be given as prescribed in Annexure X. Every test report must have remarks (i.e.) Standard Quality or Not of Standard Quality with respect to protocol applied.**

4.9.5 Reports should be in A4 size paper of good quality.

4.9.6 Reports should have Sl.No., Description of tests, Specifications, Results obtained and the reference monograph.

4.9.7 Protocols of test applied shall be furnished along with the test report. Spectra /Chromatography data sheets, where ever applicable shall also be furnished.

4.9.8 All test reports should be submitted to the KMSCL in triplicate. In case of failure of a sample, the result should be communicated immediately to the Managing Director through Phone/Fax/E-mail and the report should be sent with protocol.

4.9.9 If under any circumstances (like break down of instrument, non availability of reference standard etc.) the Analytical Laboratory is unable to undertake analysis for samples, the same should be reported within 24 hours of receipt of such samples by FAX or E-mail and the samples should be returned to the Quality Control Section, Kerala Medical Services Corporation Limited, Thiruvananthapuram. Return of samples under false claims of mal-functioning of equipment/ break-down of systems etc will be deemed as fraudulent practices and the contract will be liable to be terminated and the laboratory be black-listed without prejudice to criminal proceedings for breach of trust and other such offences.

4.9.10 Every care will be taken for proper packaging of the sample to ensure safe and intact delivery to the laboratory. If, however, any sample is received in a damaged condition by the laboratory, the sample should not be analyzed and the information should be sent immediately to the Quality Control Section, Kerala Medical Services Corporation Limited, Thiruvananthapuram by FAX or E-mail. Deliberate attempt to damage or damaging of the package after receipt shall amount to fraudulent practice leading to termination of contract, black-listing and criminal proceeding for breach of trust, contract etc.

4.9.11 In the case of Non-Pharmacopoeial Products the Method of Analysis should be appended to the Report.

4.9.12 Test Results shall be sent through e-mail to kmsclqcresults@gmail.com followed by signed hardcopies and with authorized persons name & signature.

4.9.13 Furnishing of incomplete/inconsistent/ incorrect/ unreliable test results for three times or more during the contract will lead to the termination of contract of the laboratory. Corporation will initiate blacklisting process and the lab will be blacklisted for a period of three years immediately from the date of such order and the Offerer will be ineligible to participate in any of the offers/tenders of the Corporation for a period of three years.

4.9.14 If submitted test reports is found to be incomplete/inconsistent/incorrect/ unreliable, those test reports will not be consider as test reports and the payment regarding the same will be forfeited.

4.9.15 Furnishing of three or more delayed test reports occurred during the contract, such practices will considered as default reporting and its lead to the termination of contract. Corporation will initiate blacklisting process and lab will be blacklisted for a period of three years from the date of such order making them ineligible to participate in any of the offers / Tender of the Corporation.

4.9.16 Any change/replacement of the authorized person/persons who is responsible for the signing of the test report should be intimated to the Corporation within 15 days. If no intimation received from the Laboratory, it will be considered as fraudulent practice and will initiate blacklisting process.

4.10 Payment Provisions:

4.10.1 No advance payments towards Analysis of drugs will be made.

4.10.2 Payments towards the Analysis of drugs will be made strictly as per terms and conditions laid down in the EOI document and the decisions of the EOI Inviting Authority. All payments will be made only by way of electronic fund transfer in favour of the laboratory.

4.10.3 All bills / Invoices in triplicate is to be submitted directly to the Headquarters.

4.10.4 If at any time during the period of contract, the testing fee of any items is reduced by the Offerer himself or the taxes levied is brought down by any law or Act of the Central or State Government the Offerer shall be bound to inform Corporation immediately about such reduction in the contracted prices. The EOI Inviting Authority is empowered to unilaterally effect such reduction as is necessary in rates in case the Offerer fails to notify or fails to agree for such reduction of rates.

4.10.5 The Offerer shall be responsible for payment of any charges due to any statutory authorities such as Income Tax, Sales Tax, Service tax, and

Customs Duties etc. In the event, if it is found that there is some statutory deduction to be made at the source, the Corporation will have the authority to do so.

4.10.6 If at any time during the operation of the contract, any new/ additional statutory tax or other levy is imposed to the testing of the drugs and other items or if the statutory taxes, levies, duties etc applicable are increased, if the documentary evidence for increase in the statutory taxes, levies, duties etc is produced, then the invoice amount with the enhanced rates will be admitted, after due verification.

4.11 Saving Clause:

4.11.1 No suit, prosecution or any legal proceedings shall lie against Corporation or any person for anything that is done in good faith or intended to be done in pursuance of tender.

4.12 Applicable Law & Jurisdiction of Courts:

4.12.1 The contract shall be governed by and interpreted in accordance with the laws of India for the time being in force.

4.12.2 Any and all disputes arising out of this EOI will be subject only to the jurisdiction of courts of law / tribunals situated in Thiruvananthapuram city or normally having territorial jurisdiction over Thiruvananthapuram city only or the High Court of Kerala as applicable. It is possible that jurisdiction to file disputes may available before courts of law, including High Courts / Tribunals situated elsewhere. However, the Offerers should specifically agree and covenant not to file any legal proceedings before any such courts of law / tribunal and should undertake and bind themselves to initiate and carry on legal proceedings in respect of this EOI exclusively before the Courts of law /Tribunals situated in or normally having territorial jurisdiction over Thiruvananthapuram city, or the High Court of Kerala as applicable. Any offerer who violates these conditions will be held to have indulged in an unacceptable / unfair practice and will be deemed ineligible to participate in any of the offers/tenders of the Corporation for a period of two years from the date of the breach/violation of the aforesaid conditions.

4.12.3 The Offerers are also required to abstain from printing the words“ subject to jurisdiction of Delhi Courts only’ etc from on the invoices submitted, which may force the Corporation to entertain the payment only after the Offerer undertakes in writing his/ her agreeing to the conditions above in respect of the jurisdiction of the courts of Kerala. Any such statement made in any of the document presented to the EOI Inviting Authority will be inconsistent with the terms and conditions of the EOI and the agreement thereof and the

EOI Inviting Authority will not be party to the legal situations that might arise in pursuance of such statements.

4.13 Corrupt or Fraudulent Practices

4.13.1 It is required by all concerned namely the offerers / Successful offerers etc to observe the highest standard of ethics during the process, execution and operation of the contracts. In pursuance of this policy, the Corporation defines, for the purposes of this provision, the terms set forth below as follows:

4.13.2 "Corrupt practice" means the offering, giving, receiving or soliciting of anything of value to influence the action of a public official in the Quality control process or in contract execution and operation; and

4.13.3 "Fraudulent practice" means a misrepresentation of facts in order to influence a procurement process or the execution or operation of a contract to the detriment of the EOI Inviting Authority, and includes collusive practice among offerers (prior to or after EOI submission) designed to establish testing fees at artificial non-competitive levels and to deprive the Corporation of the benefits of fair offer. Such other acts termed as fraudulent practices elsewhere in this document or any act to deceive the Corporation or any of its employees or any act adversely affecting or calculated to affect the normal/proper function or activities of the Corporation.

4.13.4 The EOI Inviting Authority will reject a proposal for award if it finds that the Offerer recommended for award has engaged in corrupt or fraudulent practices in fixing the testing fee and will declare a lab ineligible, either indefinitely or for a stated period of time, to be awarded a contract by the Corporation if it at any time determines that the lab has engaged in corrupt or fraudulent practices in fixing the testing fee, or in executing the contract.

4.13.5 No Offerer shall contact the Corporation or any of its officers or any officers of the Government on any matter relating to its offer so as to influence the members of various committees or the official(s) of EOI Inviting Authority. Any such act shall also constitute a fraudulent/ corrupt practice and would result in rejection of the EOI offer.

4.13.6 The Offerer shall not be in any way interested in or concerned directly or indirectly with, any of the officers, subordinates or servants of the Corporation in any trade or business or transactions nor shall the Offerer give or pay promise to give or pay any such officers, subordinates or servants directly or indirectly any money or fee or other considerations under designation of "Custom" or otherwise, nor shall the Offerer permit any person or persons whom so ever to interfere in the management or

performance hereof under the power of attorney or otherwise without the prior consent in writing of the EOI Inviting Authority. Any such effort by the Offerer to influence the Corporation or its officers may result in rejection of the EOI offer. The terms 'Officers, subordinates or servant' shall include their family members or other associates also.

4.13.7 If it is revealed that the analytical Laboratory is involved in any form of fraud and collusion with the suppliers of Kerala Medical Services Corporation Limited, the analytical Laboratory will be blacklisted for a period of five years. The Offerer shall also be liable for action under criminal law and the matter will be notified to the concerned Director of Drugs Control for penal action against them.

4.14 Force Majeure

4.14.1 For purposes of this clause, Force Majeure means an event beyond the control of the successful Offerer and not involving the Empanelled laboratory's fault or negligence and which is not foreseeable and not brought about at the instance of, the party claiming to be affected by such event and which has caused the non – performance or delay in performance. Such events may include, but are not restricted to, acts of the Corporation either in its sovereign or contractual capacity, wars or revolutions, hostility, acts of public enemy, civil commotion, sabotage, fires, floods, explosions, epidemics, quarantine restrictions, strikes excluding by its employees, lockouts excluding by the management, and freight embargoes. Scarcity of reagents, reference materials and power cut are not considered as force majeure.

4.14.2 If a Force Majeure situation arises, the Empanelled laboratory shall promptly notify the Corporation in writing of such conditions and the cause thereof within ten days of occurrence of such event. The time for completing the reporting may be extended by the Corporation at its discretion for such period as may be considered reasonable.

4.14.3 In case due to a Force Majeure even if the Corporation is unable to fulfill its contractual commitment and responsibility, then it will notify the Empanelled laboratory accordingly and subsequent actions taken on similar lines described in above sub-paragraphs.

4.15 Procedure for Blacklisting

4.15.1 For blacklisting a laboratory for defaulted reporting, a registered notice shall be issued to the laboratory calling for explanation within 15 days from the date of receipt of notice. On receipt of the explanation from the Laboratory, the EOI inviting Authority, may take appropriate action on merits of the case and impose blacklisting of the particular laboratory by passing appropriate orders.

4.15.2 If any NABL lab, at any stage of EOI process or thereafter in the event of being found after verification by the EOI Inviting Authority / award of contract, to indulge in fraudulent practices or concealment or misrepresentation of facts, in respect of the claims of the offer, shall be rejected, the agreement will be terminated and the bidder is liable to be blacklisted.

4.15.3 If the empanelled NABL lab is terminated / blacklisted / debarred/disqualified by any other State/Central Govt. organization after EOI submission/award of contract/execution of agreement, the NABL lab will be liable for Blacklisting/ Termination of contract.

4.15.4 Failure to inform the termination/blacklisting / debarring/disqualifying by any other State/Central Govt. organization during the empanelment with KMSCL within a period of 30 days of such order, Corporation will blacklist the empanelled NABL lab for a period up to 3 years from the date of such order.

4.16 Provisions for Appeal

4.16.1 A laboratory which has been blacklisted by the Corporation may, within 15 days from the date of receipt of such order, appeal to the State Government. The State Government after such enquiry into the matter, as is considered necessary, and after giving the said supplier an opportunity for representing his views, may pass such order in relation thereto as it thinks fit.

4.17 Termination of Contract

4.17.1 Termination for default:- The Corporation without prejudice to any other contractual rights and remedies available to it (the EOI Inviting Authority), may, by written notice of default sent to the successful offerer (Empanelled laboratory), terminate the contract in whole or in part, if the successful offerer fails to perform any other contractual obligation(s) within the time period specified in the contract.

4.17.2 Unless otherwise instructed by the EOI Inviting Authority, the successful Offerer (Empanelled laboratory) shall continue to perform the contract to the extent not terminated.

4.17.3 Termination for insolvency: If the successful offerer becomes bankrupt or otherwise insolvent, the Corporation reserves the right to terminate the contract at any time, by serving written notice to the successful Offerer without any compensation, whatsoever, to the successful Offerer (Empanelled laboratory), subject to further condition that such termination will not prejudice or affect the rights and remedies which have accrued and / or will accrue thereafter to the EOI Inviting Authority.

4.17.4 Termination for convenience: - The Corporation reserves the right to terminate the contract, in whole or in part for its (EOI Inviting Authority's) convenience, by serving written notice on the successful Offerer (Empanelled laboratory) at any time during the currency of the contract. The notice shall specify that the termination is for the convenience of the EOI Inviting Authority. The notice shall also indicate interalia, the extent to which the successful offerers performance under the contract is terminated, and the date with effect from which such termination will become effective.

4.17.5. Termination due to change of ownership, constitution, suspension/ cancellation of statutory approval/ certification, accreditation etc.

4.17.6. Where there is a change of ownership (in the case of sole proprietorship unit) of the Empanelled laboratory under contract, the contract will stand automatically terminated. The owner of the Empanelled laboratory shall inform the change of ownership to the EOI Inviting Authority as soon as the change takes place. The new owner will be eligible for a fresh contract for the remaining period of the earlier contract with the former owner under the same terms and conditions on deposit of the performance security amount. Inspection of the unit will be the discretion of the EOI Inviting Authority.

4.17.7. Where there is a change of constitution of the firm running the Empanelled Laboratory, the contract will stand terminated from the date of change of constitution if the person(s) responsible for the firm for the contract and its day to day operations change. In such an event the new firm will be eligible for further fresh contract for the remaining period of the earlier contract with the firm under the same terms and conditions. The performance security deposited earlier may be adjusted for the fresh contract on mutual agreement.

4.17.8. Where there is temporary or permanent suspension/ cancellation/ withdrawal/ revoking of the statutory approval/ certification/ accreditation on the basis of which the laboratory was empanelled and contract was awarded, the contract will stand terminated from the date of such action coming into force. Such termination may, however, be withdrawn if the action is cancelled or stayed by any competent forum. It will be onus of the Empanelled laboratory to report any such action taken against it.

(Sd/-)

Managing Director, KMSCL
&
(EOI Inviting Authority)

ANNEXURE-I

CHECK LIST

Name of the Laboratory : _____

Address : _____

Sl. No	Documents to be submitted	Page No
1.	Checklist (Annexure –I) for the list of documents enclosed with their page Nos. The documents should be serially numbered and arranged as per Annexure–I.	
2.	EOI Document Cost in the form of DD shall be kept in an envelope. DD No & date: Bank & branch: Amount in Rs:	
3.	Earnest Money Deposit the form of DD shall be kept in an envelope, **IF NOT EXEMPTED**, DD No & date: Bank & branch: Amount in Rs: **IF EXEMPTED** as per clause 4.2.4 valid documentary evidence to prove the claim.	
4.	Copy of notarized Documentary evidence for the constitution of the company /concern such as Memorandum and Articles of Association, along with notary attested copies of Form 32 whenever there is a change of Directors, Latest Partnership deed (Notary attested copy), Bye law in the case of society, trust etc. with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor/ other responsible persons/ office bearers. The list of present MD & Directors of the firm shall	

Sl. No	Documents to be submitted	Page No
	also be furnished separately.	
5.	Annual turnover statement certified by the auditors for last three years i.e., 2015-16,2016-2017 & 2017-18 as in (Annexure-V)	
6.	Notary Attested Photocopy of approval for testing of Drugs and the list of drugs approved for testing in the laboratory issued by the Drugs Control Authority and valid renewal with list of approved products for testing.	
7.	Notary Attested Photocopy of valid GLP Certificate issued by the Drugs Control Authority and valid renewal.	
8.	Notary Attested Photocopy of NABL accreditation certificate and its valid renewal.	
9.	Service Tax Clearance Certificate issued by the concerned authority and attested copy of certificate of registration for service tax.	
10.	Notary attested copies of audited Balance Sheet and Profit and Loss account for the last three years i.e. 2015-16,2016-2017 & 2017-18.	
11.	The list of qualified personnel employed in the laboratory (Employees name, Qualification and experience)	
12.	The list of sophisticated analytical equipments & apparatus available in the laboratory. [Annexure III]	
13.	Duly filled performance statement in Annexure IV.	
14.	Declaration in the Proforma given in Annexure-VI duly signed and notarized	
15	Details of Analytical Laboratory in Annexure–II.	
16.	Consent letter of the offerer as in Annexure VII.	
17	EOI document signed by the offerer in all pages with office seal	
18	Notary attested copy of PAN.	

ANNEXURE – II

DETAILS OF ANALYTICAL LABORATORY

Sl.No.	Particulars	Details (To be filled in by the EOI Responder)
1.	Name of the Organization	
2.	Address(Regd. Office): Telephone: Fax: E-mail: Website:	
3.	Address(Laboratory Premises)***** Telephone: Fax: E-mail: Website: (***** If testing of the items are performed in more than one premises, details of all such units shall be furnished.)	
4.	Name of the Contact Person: Designation Telephone: Mobile: E-mail ID:	
5.	Type of the Organization (Public Sector/Limited/ Private Limited/Partnership/ Proprietary/Any Other):	
6.	Date of inception of the firm	
7.	Chief Officer of the Organization: Designation: E-mail ID: Telephone:	
8.	Registration No. & Date of Incorporation of Company:	
9.	License No. issued by the	

Sl.No.	Particulars	Details (To be filled in by the EOI Responder)
	Drugs Control Dept. of the state for conducting the Analysis. Date of issue and current validity of the license period shall also be specified.	
10.	PAN no:	
11.	List of minimum 3 Clients as per clause No.3.2.5 (Provide number of samples, type, contact details like Address, Contact Person, e-mail ID, Telephone)	
12.	Total No. of Employees: 1. Technical Staff 2. Non-Technical Staff (Details of qualified personnels for testing of drugs/supplies)	
13.	Authorized Person/Persons responsible for signing the test report: 1. No: of Person/Persons 2. His/Her Name & Designation	
14.	Whether the License/Approval/ accreditation of the laboratory was cancelled / suspended by the authority in the past, if yes give details.	
15.	Whether any prosecution action is in progress or pending against the laboratory or any of its. Furnish details of past conviction(s), if any.	

Date: Seal: Authorized Signatory:

ANNEXURE- III

LIST OF SOPHISTICATED ANALYTICAL EQUIPMENTS & APPARATUS AVAILABLE IN THE LABORATORY

Name of the Laboratory : _____

Address : _____

Name of the Equipment/ Instruments/Apparatus	Name & Description	Date of Installation	Working Conditions
FACILITIES IN THE MICROBIOLOGICAL SECTION			
List of Equipments / Apparatus Available with Date of Installation (eg. Incubators, Autoclave etc.)			

Date: Seal: Authorized Signatory:

ANNEXURE- IV

PROFORMA FOR PERFORMANCE STATEMENT

(for a period of last 3 years)

Name of the Laboratory : _____

Address : _____

_____

Types of Samples Analyzed		No. of Samples Analyzed during		
		2015-16	2016-17	2017-18
1	Tablets / Capsules			
2	Injectable			
3	Liquid Orals			
4	Ointments / Creams / Gels			
5	Surgicals (Specify item names)			
6	Sutures (Specify types)			
7	Other Categories (Specify)			
8	Other Categories (Specify)			

Signature :
Date :
Name of the Lab :
Office Seal :

ANNEXURE- V

ANNUAL TURN OVER STATEMENT

I hereby certify that M/s _____ (Name & address _____) who is participating in the **EOI No. KMSCL/QC/EOI/2019/01 DATED 15.11.2018** of KMSCL is having the following annual turnover and the statement is true and correct.

Sl. No.	Year	Turnover (Rs.)
1.	**2015 – 2016**	
2.	**2016 - 2017**	
3.	**2017 - 2018**	
Total (Rs.)		
Average turnover per annum (Rs.)		

Date:

Signature of Auditor/
Chartered Accountant

(Name in Capital) :
Name of firm :

Reg. No. :

Seal:

ANNEXURE-VI

DECLARATION

I / We …… (Name of the laboratory) having our office at ……
……
Lababoratory at …… …… …… …… do declare that I / We have carefully read all the conditions of **EOI No. KMSCL/QC/EOI/2019/01 DATED 15.11.2018** of Kerala Medical Services Corporation Ltd., Thiruvananthapuram, for the EOI floated for empanelment of analytical testing laboratories for the analysis of drugs and supplies, for a period of two years from the date of acceptance and abide by all conditions set forth therein. I/We do accept(s) all the terms and conditions of the above EOI document including amendments of the tender, if any, published by the Corporation.

`

Signature :
Date :
Name of the Lab :

Office Seal :

ATTESTED BY NOTARY PUBLIC

ANNEXURE-VII

CONSENT LETTER OF THE OFFERER

From

Name of the Laboratory……..

Address ……..

To

The EOI Inviting Authority

Sir,

Sub: Consent for performing complete analysis of drugs/supplies.

Ref : KMSCL/QC/EOI/2019/01 dated 15.11.2018

With reference to the EOI for the empanelment of drugs testing laboratories, we here by submit our consent to perform the complete analysis of the following items of drugs/supplies in Appendix I-A & Appendix I-B of the EOI document at the rates offered in column 6 of the following tables and as per the conditions stipulated in the EOI documents referred above.

Table.I **LIST OF ITEMS OFFERED IN APPENDIX I-A**

Sl.No.	Category	Drug Code	Drug Name	Strength	Unit	Agreed rate (Rs.)
(1)		(2)	(3)	(4)	(5)	(6)

Table.II **LIST OF ITEMS OFFERED IN APPENDIX I-B**

Sl.No.	Category	Drug Code	Drug Name	Strength	Unit	Offered rate (Rs.)
(1)		(2)	(3)	(4)	(5)	(6)

Date: Seal: Authorized Signatory:

ANNEXURE-VIII

FORMAT OF BANK GUARANTEE FOR SECURITY DEPOSIT

To
The Kerala Medical Services Corporation Limited
(Address)

WHEREAS _____ (Name and address of the Laboratory) has undertaken, in pursuance of contract no_____ dated _____ (herein after called "the contract") to conduct quality control analysis for Kerala Medical Services Corporation Limited, (address).

AND WHEREAS it has been stipulated by you in the said contract that the Laboratory shall furnish you with a bank guarantee by a scheduled commercial bank recognised by you for the sum specified therein as security for compliance with its obligations in accordance with the contract;

AND WHEREAS we have agreed to give the Laboratory such a bank guarantee;

NOW THEREFORE we hereby affirm that we are guarantors and responsible to you, on behalf of the Laboratory, up to a total amount of _____ (Amount of the guarantee in words and figures), and we undertake to pay you, upon your first written demand declaring the Laboratory to be in default under the contract and without cavil or argument, any sum or sums within the limits of (amount of guarantee) as aforesaid, without your needing to prove or to show grounds or reasons for your demand or the sum specified therein.

We hereby waive the necessity of your demanding the said debt from the Laboratory before presenting us with the demand.

We undertake to pay you any money so demanded notwithstanding any dispute or disputes raised by the Laboratory (s) in any suit or proceeding pending before any Court or Tribunal relating thereto our liability under these presents being absolute and unequivocal.

We agree that no change or addition to or other modification of the terms of the contract to be performed there under or of any of the contract documents

which may be made between you and the Laboratory shall in any way release us from any liability under this guarantee and we hereby waive notice of any such change, addition or modification.

No action, event, or condition that by any applicable law should operate to discharge us from liability, hereunder shall have any effect and we hereby waive any right we may have to apply such law, so that in all respects our liability hereunder shall be irrevocable and except as stated herein, unconditional in all respects.

This guarantee will not be discharged due to the change in the constitution of the Bank or the Laboratory (s).

We, _____ (indicate the name of bank) lastly undertake not to revoke this guarantee during its currency except with the previous consent, in writing, of The Kerala Medical Services Corporation Limited.

This Guarantee will remain in force up to---------- (Date). Unless a claim or a demand in writing is made against the bank in terms of this guarantee on or before the expiry of ---------- (Date) all your rights in the said guarantee shall be forfeited and we shall be relieved and discharged from all the liability there under irrespective of whether the original guarantee is received by us or not.

(Signature with date of the authorised officer of the Bank)
……
Name and designation of the officer
……
……
Seal, name & address of the Bank and address of the Branch

ANNEXURE-IX

AGREEMENT

THIS AGREEMENT made on this ……. day of ……, 20… between …….. Kerala Medical Services Corporation Ltd represented by its Managing Director (& Expression of Interest (EOI) Inviting Authority) having its registered office at Thiruvananthapuram (hereinafter mentioned as "The KMSCL" or the Corporation) of one part and M/s. ……
……
… (Name and Address of the laboratory)(hereinafter called as "The Empanelled laboratory" or the "Laboratory" in short) represented by …… (Name of the authorized signatory and Designation), aged ……. Years, residing at …….. (Full residential address of the signatory) of the other part.

WHEREAS the KMSCL had invited Expression of Interest (EOI) from eligible Analytical Laboratories for test and analysis of Drugs and other consumables procured by it for supply to the healthcare institutions under the Health & Family Welfare Department of Kerala as per the EOI document number .....dated ..... and had prescribed eligible criteria and various terms and conditions for participation and presentation of the EOI, and

WHEREAS The Empanelled Laboratory above has offered to the KMSCL to undertake analytical work of the list of items mentioned in the Annexure attached hereto, in accordance with the terms and conditions specified in the above said EOI document, at the rates noted therein and had given an undertaking in writing to those effects and in the manner and under the terms and conditions hereinafter mentioned, and

WHERAS the EOI Inviting Authority (KMSCL) has accepted the offer, and

The Empanelled Laboratory has deposited with the KMSCL a sum of Rs.50,000/-(Rupees Fifty Thousand) as Security Deposit for the due and faithful performance of this Agreement and liable to be forfeited as

liquidated damages in the event of the Laboratory failing duly and faithfully to perform its obligations set forth hereinafter.

In this agreement words and expressions shall have the same meanings as are respectively assigned to them in the EOI document referred to.

Now therefore these presents witness that for carrying out the said Agreement in this behalf into execution, The Empanelled Laboratory and the KMSCL do hereby mutually covenant ,declare, contract and agree each of them with the other of them in the manner following, that is to say,

1. The term "Agreement", wherever used in this connection, shall mean the terms and conditions stipulated hereinafter for the analysis of Drugs, surgical and other items for the year 2019 -21.

2. (a) The agreement is for undertaking analysis of Drugs, Surgical items & Sutures items by the Empanelled Laboratory to the KMSCL of the samples specified in the …… (will specify later) attached hereto at the rates noted against each therein on the terms and conditions set forth in this Agreement and strictly within the time frame stipulated for the respective items in clause 3.1 of the EOI document.

(b) This agreement shall be deemed to have come into force with effect from ---------- (Date of execution of agreement) and it shall remain in force for a period of two years with effect from that date and may however be extended for a further period, on mutually agreed terms signed by both parties.

(c) The time frame specified in clause 3.1 of the EOI document for the respective item shall be strictly adhered to by the Laboratory. Tests and Analysis of drugs and other items will be performed in accordance with the statutory standards such as IP, BP, USP, BIS etc and in the case of items for which no official standards, by applying such recognized or prescribed or authentic parameters of standard quality and the test reports shall reach the KMSCL within the maximum time limit specified in the EOI document reckoned from the date on which the item to be tested is delivered to the Empanelled Laboratory, failing which the measures of penalty and others specified will be applicable.

(d) The test reports are to be submitted to the KMSCL by email within the time period specified in clause 3.1 of the EOI document at the email address

of the KMSCL (kmsclqcresults@gmail.com) to be followed by three sets of hardcopies duly authenticated.

(e) In the event of any failure/default/deviations from the EOI agreement on the part of the Empanelled Laboratory with or without any quantifiable loss to the KMSCL, the amount of the performance security is liable to be forfeited. If the Empanelled Laboratory withdraws from the contract during the period of contract, the security deposit shall be liable to be forfeited, the contract terminated and the Empanelled Laboratory shall be liable to be blacklisted for a period of three years from the date of such order making them ineligible to participate in any of the offers/Tender of the Corporation.

3. In respect of the analysis of items in the Schedule, the Laboratory shall allow inspection of the laboratory at any time during the continuance of the contract period by a team of Experts/Officials whom the KMSCL may depute for the purpose. The laboratory shall extend all facilities to the team to enable them to inspect sample storage, reagents, instruments, all relevant records, analysis etc, in the Empanelled Laboratory and also to take photographs of such facilities, which shall not be used by the Corporation other than pursuance of actions under the terms and conditions of this contract and also of the EOI document.

4. All expenses, damages and other moneys payable to the KMSCL by the Empanelled Laboratory under any provisions of this Agreement may be recovered from the amounts due or subsequently becoming due from the KMSCL to the Laboratory under this or any other Agreement. In case such amount are insufficient to fully cover such expenses, damages or other moneys payable. It shall be lawful for the KMSCL to recover the balance amount from the security deposit of the laboratory and all other money held by KMSCL and in case such security deposit is insufficient then it shall be also be lawful for the KMSCL to recover the residue of the expenses, damages and moneys, if necessary by means of legal proceeding against the Empanelled Laboratory.

5. The amount of security deposit remitted by the Laboratory to the KMSCL by way of Demand Draft by favoring the Managing Director, KMSCL, Thiruvananthapuram will be returned on successful fulfillment of the terms and conditions of this agreement without any interest.

6. (a) No advance payment towards any analysis will be made to the Empanelled Laboratory.

(b) All bills/invoices should be raised in triplicate in the name of the managing director Kerala Medical Services Corporation Limited. All payments will be made only by way of electronic fund transfer in favour of the Empanelled Laboratory for which bank details shall be furnished to the Corporation at the time of entering into agreement.

(c) The Empanelled Laboratory shall furnish the test reports within:

I. 15 days of receipt of the samples in case of Tablets, Capsules, Pessaries, Ointments, Powders and Liquid Oral Preparations, and all Non- Sterile preparations

II. 30 days of receipt of the samples in the case of all sterile preparations.

7. The Empanelled Laboratory shall not at anytime assign, sub-let or make over the present Contract or the benefits thereof or any part thereof, to any person or persons whomsoever.

8. The following documents shall be deemed to form and be read and construed as part of this Agreement, viz.:

(a) All the documents submitted by the Empanelled Laboratory as a part of the EOI offer,

(b) The Schedule of Requirements;

(c) The Specifications and other quality parameters;

(d) The clarifications and amendments issued / received as part of the EOI Document

(e) All correspondence as part of tender during or after the date of agreement accepted by Tender Inviting Authority

9. The terms and conditions specified in the EOI document published by the EOI Inviting Authority in acceptance of which the Empanelled Laboratory had presented the EOI offer will apply in matters not specifically in this agreement.

10. The Empanelled Laboratory and the Corporation mutually agree that any and all disputes arising out of this Agreement will be subject only to the jurisdiction of courts of law / tribunals situated in Thiruvananthapuram city or normally having territorial jurisdiction over Thiruvananthapuram city only or the High Court of Kerala as applicable and the provisions of clause 4.12 of the EOI document are agreed to in full.

In witness whereof the parties hereto have caused this Agreement to be executed in accordance with their respective laws the day and year first above written.

Signed, Sealed and Delivered by the

said ……..... (For the EOI Inviting Authority- KMSCL)

in the presence of,

1. …….. (Signature, name and Address)

2. …….. (Signature, name and Address)

Signed, Sealed and Delivered by the

said ……..... (For the Empanelled Laboratory)
(Signature, Name and Address with Office Seal)

in the presence of,

1. …….. (Signature, name and Address)

2. …….. (Signature, name and Address)

:

:

:

:

Analysis Started :

Analysis Completed :

Details of Raw Material/Final Product :

a) Sample Quantity :

b) Drug Code/Product Code :

c) Strength :

d) :

:

:

Results of Test/Analysis with Protocol

SL. NO	TEST	RESULTS	SPECIFICATION	TEST METHOD
1.	DESCRIPTION	WHITE CIRCULAR UNCOATED TABLETS HAVING A BISECTING LINE ON ONE SIDE		
2.	IDENTIFICATION	COMPLIES	Complies with I.P	IP 2014
3.	RELATED SUBSTANCES	COMPLIES	NMT 0.25%	IP 2014
4.	DISSOLUTION	94.65%	D-NLT 80%	IP 2014
5.	UNIFORMITY OF WEIGHT	COMPLIES	NMT TWO OF THE INDIVIDUAL WEIGHT DEVIATES 5%FROM AVERAGE WEIGHT	IP 2014
6.	ASSAY AS PARACETAMOL	483.84MG/TAB (96.77%)	475 MG/TAB TO 525 MG/TAB (95% TO 105%)	IP 2014

LABEL CLAIM: 500MG/TAB
COMPLIES TO IP 2014

Laboratory Seal

FOR AND ON BEHALF OF
Person In-charge of Testing

Name and Designation

List of items with pre-fixed laboratory testing rates

APPENDIX-IA

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
1	ACD	D24056C	ACTINOMYCIN D INJ	0.5mg/3ml	Vial	825
2	ACD	D24058C	ANASTRAZOLE TAB IP	1mg	1 No	990
3	ACD	D24167C	AZATHIOPRINE TAB IP	50mg	1 No	685
4	ACD	D24061C	BICALUTAMIDE TAB IP	50mg	1 No	913
5	ACD	D24062C	BLEOMYCIN INJ IP	15mg	Vial	968
6	ACD	D24063C	BORTEZOMIB INJ IP	2mg	Vial	668
7	ACD	D24180C	BUSULPHAN TAB IP	2 mg	1 no	1035
8	ACD	D24066C	CAPECITABINE TAB IP	500mg	1 No	693
9	ACD	D24067C	CARBOPLATIN INJ IP	150mg	Vial	1155
10	ACD	D24068C	CARBOPLATIN INJ IP	450mg	Vial	1155
11	ACD	D24071C	CISPLATIN INJ IP	10mg	Vial	1155
12	ACD	D24072C	CISPLATIN INJ IP	50mg	Vial	1155
13	ACD	D24070C	CHLORAMBUCIL TAB IP	2 mg	1 no	1070
14	ACD	D24076C	CYCLOPHOSPHAMIDE TAB IP	50mg	1 No	424
15	ACD	D24074C	CYCLOPHOSPHAMIDE INJ IP	200mg	Vial	535
16	ACD	D24075C	CYCLOPHOSPHAMIDE INJ IP	500mg	Vial	535
17	ACD	D24184C	CYTARABINE INJ IP	1 gm	Vial	1045
18	ACD	D24081C	DAUNORUBICIN INJ IP	20mg	Vial	2220
19	ACD	D24077C	CYTARABINE INJ IP	100mg	Vial	1045
20	ACD	D24161C	DEXAMETHASONE TAB IP	8mg	1 No	1670
21	ACD	D24082C	DOCETAXEL INJ IP	20mg	Vial	2000
22	ACD	D24083C	DOCETAXEL INJ IP	80mg	Vial	2000
23	ACD	D24084C	DOCETAXEL INJ IP	120 mg	Vial	2000
24	ACD	D24087C	DOXORUBICIN INJ (LYOPHILISED) IP	10mg	Vial	1210
25	ACD	D24088C	DOXORUBICIN INJ (LYOPHILISED) IP	50mg	Vial	1210
26	ACD	D24092C	EPIRUBICIN INJ BP	10mg	Vial	1100
27	ACD	D24093C	EPIRUBICIN INJ BP	50mg	Vial	1100
28	ACD	D24094C	ERLOTINIB TAB IP	100 mg	1 no	1265
29	ACD	D24095C	ERLOTINIB TAB IP	150 mg	1 no	1264
30	ACD	D24096C	ETOPOSIDE CAP IP	50mg	Vial	1420
31	ACD	D24054C	FLUROURACIL INJ IP	250mg	Amp	1073
32	ACD	D24055C	FLUROURACIL INJ IP	500mg	Amp	1420
33	ACD	D24103C	GEFITINIB TAB IP	250mg	1 No	715
34	ACD	D24105C	GEMCITABINE INJ IP	1gm	Vial	1320
35	ACD	D24104C	GEMCITABINE INJ IP	200mg	Vial	1320
36	ACD	D24109C	IBANDRONATE TAB	50mg	1 No	770
37	ACD	D24110C	IFOSFAMIDE WITH MESNA INJ	1gm	Vial	1183

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
38	ACD	D24111C	IFOSFAMIDE WITH MESNA INJ	2gm	Vial	1183
39	ACD	D24164C	IMATINIB TAB IP	400mg	1 No	589
40	ACD	D24165C	IMATINIB TAB IP	100mg	1 No	589
41	ACD	D24116C	IRINOTECAN INJ IP	100mg	Vial	1073
42	ACD	D24115C	IRINOTECAN INJ IP	40mg	Vial	1073
43	ACD	D24119C	LENALIDOMIDE CAP	10mg	1 No	660
44	ACD	D24163C	LENALIDOMIDE CAP	5mg	1 No	660
45	ACD	D24120C	LETREZOLE TAB IP	2.5mg	1 No	825
46	ACD	D24121C	LEUPROLIDE ACETATE INJ	3.75mg	Vial	1100
47	ACD	D24123C	LOMUSTINE CAP IP	40mg	1 No	770
48	ACD	D24125C	MESNA INJ	200mg	Amp	963
49	ACD	D24127C	METHOTREXATE INJ IP	50mg	Vial	1089
50	ACD	D24166C	METHOTREXATE INJ IP (INTRATHECAL, PESERVATIVE FREE)	15mg	Vial/PFS	1089
51	ACD	D24128C	METHOTREXATE TAB IP	2.5mg	1 No	495
52	ACD	D24129C	MITOMYCIN INJ	2mg	Vial	1210
53	ACD	D24130C	MITOMYCIN INJ	10mg	Vial	1210
54	ACD	D24131C	MITOZANTRONE INJ	20mg	Vial	1320
55	ACD	D24133C	OXALIPLATIN INJ IP	50mg	Vial	1182
56	ACD	D24134C	OXALIPLATIN INJ IP	100mg	Vial	1182
57	ACD	D24136C	PACLITAXEL INJ IP	30mg	Vial	1100
58	ACD	D24137C	PACLITAXEL INJ IP WITH CODON SET	100mg	Vial	1100
59	ACD	D24138C	PACLITAXEL INJ IP WITH CODON SET	260mg	Vial	1100
60	ACD	D24139C	PACLITAXEL INJ IP WITH CODON SET	300 mg	Vial	1100
61	ACD	D24141C	PEMETREXED INJ IP	100mg	Vial	1073
62	ACD	D24142C	PEMETREXED INJ IP	500mg	Vial	1073
63	ACD	D24143C	PROCARBAZINE HCL CAP	50mg	1 No	407
64	ACD	D24147C	SORAFENIB TOSYLATE TAB IP	200mg	1 No	584
65	ACD	D24150C	TAMOXIFEN TAB IP	20mg	1 No	715
66	ACD	D24151C	TEMOZOLOMIDE CAP IP	20mg	1 No	583
67	ACD	D24152C	TEMOZOLOMIDE CAP IP	100mg	1 No	583
68	ACD	D24153C	TEMOZOLOMIDE CAP IP	250 mg	1 No	583
69	ACD	D24154C	THALIDOMIDE CAP	100mg	1 No	770
70	ACD	D24160C	ZOLEDRONIC ACID INJ IP	4mg	Vial	963
71	CAT-I	D01019	ACECLOFENAC TAB IP	100mg	1 No	341
72	CAT-I	D19006	ACETAZOLAMIDE TAB IP	250mg	1 No	535
73	CAT-I	D13036	ACETYL SALICYLIC ACID TAB IP(GASTRO-RESISTANT)	150mg	1 No	418

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
74	CAT-I	D13024	ACETYLSALICYLIC ACID TAB IP(GASTRO-RESISTANT)	75mg	1 No	418
75	CAT-I	D06002/12	ACTIVATED CHARCOAL IP	10gm	Packet	220
76	CAT-I	D09003	ACYCLOVIR CREAM IP	5% w/w	5gm Tube	751
77	CAT-I	D15014	ACYCLOVIR EYE OINTMENT IP	3%	5gm Tube	619
78	CAT-I	D09001	ACYCLOVIR INJ IP	250 mg	Vial	751
79	CAT-I	D09002/12	ACYCLOVIR TAB IP	400 mg	1 No	751
80	CAT-I	D13062	ADENOSINE INJ IP	3mg/ml	2ml amp	2120
81	CAT-I	D05005	ADRENALINE BITARTRATE INJ IP	1mg/ml	1 ml Amp	1593
82	CAT-I	D08015	ALBENDAZOLE ORAL SUSPENSION IP	200 mg/5ml	10 ml Bottle	418
83	CAT-I	D08001	ALBENDAZOLE TAB IP	400 mg	1 No	460
84	CAT-I	D01013	ALLOPURINOL TAB IP	100 MG	1 No	501
85	CAT-I	D17007/12	ALPRAZOLAM TAB IP	0.25mg	1 No	584
86	CAT-I	D02091	AMIKACIN SULPHATE INJ IP	250mg/2ml	2ml Vial	751
87	CAT-I	D03003	AMINOPHYLLINE INJ IP	25mg/ml	10ml Amp	642
88	CAT-I	D13040	AMIODARONE INJ IP	50mg/ml	3 ml	759
89	CAT-I	D13041	AMIODARONE TAB IP	100mg	1 No	668
90	CAT-I	D17005	AMITRIPTYLINE TAB IP	25mg	1 No	668
91	CAT-I	D13031/12	AMLODIPINE TAB IP(FILM COATED)	5 mg	1 No	1086
92	CAT-I	D02036/12	AMOXICILLIN AND POTASSIUM CLAVULANATE TAB IP	500mg 125mg	1 No	880
93	CAT-I	D02049	AMOXYCILLIN AND POTASSIUM CLAVULANATE INJ IP	1.2 g/10 ml	Vial	880
94	CAT-I	D02047	AMOXYCILLIN AND POTASSIUM CLAVULANATE ORAL SUSPENSION IP	(200mg 28.5mg) or (400mg + 57mg)	30 ml bottle	935
95	CAT-I	D02004	AMOXYCILLIN CAP IP	250 mg	1 No	501
96	CAT-I	D02005	AMOXYCILLIN CAP IP	500 mg	1 No	501
97	CAT-I	D02032	AMOXYCILLIN ORAL SUSPENSION IP	125 mg/5 ml	60 ml Bottle	886
98	CAT-I	D02033	AMOXYCILLIN ORAL SUSPENSION IP	250mg/5 ml	60 ml Bottle	886
99	CAT-I	D02007	AMPICILLIN CAP IP	250 mg	1 No	501
100	CAT-I	D02041	AMPICILLIN CAP IP	500mg	1 No	429
101	CAT-I	D02008	AMPICILLIN INJ IP	500 mg	Vial	1712
102	CAT-I	D08019	ARTESUNATE INJ	60mg	Vial	1045
103	CAT-I	D13008	ATENOLOL TAB IP	50 mg	1 No	1002
104	CAT-I	D13013	ATORVASTATIN TAB IP	10 mg	1 No	1252
105	CAT-I	D15016	ATROPINE EYE DROPS BP	1%	5 ml bottle	627
106	CAT-I	D15017	ATROPINE EYE OINTMENT IP	1%w/w	5gm	482
107	CAT-I	D04007	ATROPINE SULPHATE INJ IP	0.6mg/ml	1 ml Amp	1086

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
108	CAT-I	D06017	ATROPINE SULPHATE INJ IP	1mg/ml	100ml	1002
109	CAT-I	D02052	AZITHROMYCIN INJ	500mg	10 ml Vial	990
110	CAT-I	D02053	AZITHROMYCIN ORAL SUSPENSION IP	(100mg/5 ml)	30 ml bottle	770
111	CAT-I	D02093	AZITHROMYCIN ORAL SUSPENSION IP	(200mg/ 5ml)	30 ml bottle	770
112	CAT-I	D02031	AZITHROMYCIN TAB IP	500 mg	1 No	886
113	CAT-I	D01026	BACLOFEN TAB IP	5mg	1 No	770
114	CAT-I	D15018	BALANCED SALT SOLUTION FOR OPHTHALMIC USE(GLASS BOTTLE/OT PACK)	500 ml	Bottle	550
115	CAT-I	D26001	BENEDICTS REAGENT SOLUTION	500 ml	Bottle	418
116	CAT-I	D14026/12	BENZYL BENZOATE APPLICATION IP	25% w/v,	100 ml bottle	330
117	CAT-I	D02009	BENZYL PENCILLIN INJ IP	10 lakhs units	Vial	1845
118	CAT-I	D05017	BETAHISTINE TAB IP	8mg	1 No	880
119	CAT-I	D15007	BETAMETHASONE EYE DROPS IP	0.1%w/v	5ml/Bot	668
120	CAT-I	D05004	BETAMETHASONE SODIUM INJ IP	4mg/ml	1ml Amp	1002
121	CAT-I	D14009/12	BETAMETHASONE VALERATE CREAM IP	0.1%w/w	5 gm Tube	668
122	CAT-I	D14046	BETAMETHASONE DIPROPIONATE CREAM IP	0.05%w/w	10gm tube	670
123	CAT-I	D20012	BISACODYL TAB IP	5mg	1 No	668
124	CAT-I	D15021	BRIMONIDINE EYE DROPS	0.20%	5 ml	751
125	CAT-I	D11005	BROMOCRIPTINE TAB IP	1.25mg	1 No	668
126	CAT-I	D05038	BROMHEXINE TAB IP	8 MG	1 No	835
127	CAT-I	D04031	BUPIVACAINE INJ IP	0.005	20 ml vial	1670
128	CAT-I	D04017	BUPIVACAINE IN DEXTROSE INJ USP	0.50%	4 ml Amp	1139
129	CAT-I	D04030	BUPIVACAINE INJ IP	0.25%	20 ml Vial	1139
130	CAT-I	D14030/12	CALAMINE LOTION I.P	50 ml	bottle	330
131	CAT-I	D22012/12	CALCIUM CARBONATE WITH VITAMIN D3(CHOLECALCIFEROL) TAB IP	625mg + 200IU	1 No	715
132	CAT-I	D22003	CALCIUM GLUCONATE INJ IP	10%w/v	10ml	751
133	CAT-I	D07024	CARBAMAZEPINE ORAL SUSPENSION BP	100mg/5 ml	30 ml bottle	605
134	CAT-I	D07005	CARBAMAZEPINE TAB IP	200 mg	1 No	584
135	CAT-I	D11002	CARBIDOPA + LEVODOPA TAB IP	10mg+100mg	1 No	1419
136	CAT-I	D11007	CARBIDOPA + LEVODOPA TAB IP	25mg+ 100mg	1 No	1419
137	CAT-I	D15022	CARBOXYMETHYLCELLULOSE EYE DROPS IP	0.005	10 ml	270
138	CAT-I	D13070	CARVEDILOL TAB IP	25 mg	1 No	2250
139	CAT-I	D13045	CARVEDILOL TAB IP	6.25mg	1 No	798

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
140	CAT-I	D02035	CEFADROXIL TAB IP	500mg	1 No	979
141	CAT-I	D02094	CEFAZOLIN SODIUM INJ IP	1gm	Vial	2045
142	CAT-I	D02055	CEFIXIME TAB IP	200mg	1 No	990
143	CAT-I	D02056	CEFOPERAZONE + SULBACTAM INJ	1gm+ 0.5gm	Vial	638
144	CAT-I	D02010	CEFOTAXIME SODIUM INJ IP	250mg	Vial	1670
145	CAT-I	D02026	CEFOTAXIME SODIUM INJ IP	1gm	Vial	1670
146	CAT-I	D02057	CEFPODOXIME PROXETIL TAB IP	200mg	1 No	990
147	CAT-I	D02034	CEFTRIAXONE INJ IP	1gm	Vial	770
148	CAT-I	D02020	CEFUROXIME INJ IP	750 mg	Vial	1670
149	CAT-I	D02101	CEPHALEXIN CAP IP	500 mg	1 No	1665
150	CAT-I	D02112	CEPHALEXIN ORAL SUSPENSION (DRY) IP	125 mg/5ml	30 ml Bottle	668
151	CAT-I	D05018	CETIRIZINE SYRUP IP	5mg/ 5ml	30 ml Bottle	572
152	CAT-I	D05010	CETIRIZINE TAB IP	10 mg	1 No	793
153	CAT-I	D17009	CHLORDIAZEPOXIDE TAB IP	10 MG	1 No	668
154	CAT-I	D17047	CHLORDIAZEPOXIDE TAB IP	25 MG	1 No	668
155	CAT-I	D14022	CHLORHEXIDINE MOUTH WASH IP	60 ml	bottle	330
156	CAT-I	D17002	CHLORPROMAZINE TAB IP	50mg	1 No	641
157	CAT-I	D17003	CHLORPROMAZINE TAB IP	100mg	1 No	641
158	CAT-I	D13071	CHLORTHALIDONE TAB IP	12.5mg	1 No	635
159	CAT-I	D08009	CHLOROQUINE PHOSPHATE TAB IP	250 mg	1 No	668
160	CAT-I	D05008	CHLORPHENIRAMINE MALEATE INJ IP	10 mg/ml	1 ml Amp	668
161	CAT-I	D05019	CHLORPHENIRAMINE MALEATE TAB IP	4mg	1 No	877
162	CAT-I	D17035	CINNARIZINE TAB IP	25 mg	1 No	495
163	CAT-I	D15024	CIPROFLOXACIN + DEXAMETHASONE EAR DROPS	0.3 %+ 0.1 %	10 ml	825
164	CAT-I	D02063	CIPROFLOXACIN + TINIDAZOLE TAB	500mg + 600mg	1 No	894
165	CAT-I	D15002	CIPROFLOXACIN EYE/EAR DROPS IP	0.3%w/v	5mlBottle	751
166	CAT-I	D02012	CIPROFLOXACIN INJ IP	2 mg/ml	100ml Bottle	1937
167	CAT-I	D02011	CIPROFLOXACIN TAB IP	500 mg	1 No	1086
168	CAT-I	D02098	CLINDAMYCIN + CLOTRIMAZOLE VAGINAL PESSARY	100mg+ 200 mg	1 No	743
169	CAT-I	D07009	CLOBAZAM TAB IP	5 mg	1 No	668
170	CAT-I	D14031	CLOBETASOLE PROPIONATE CREAM IP	0.05%	15gm Tube	660
171	CAT-I	D16009	CLOMIPHENE CITRATE TAB IP	50mg	1 No	935
172	CAT-I	D17061	CLOMIPRAMINE CAP IP	25mg	1 No	1200

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
173	CAT-I	D17038	CLONAZEPAM TAB IP	0.5 mg	1 No	682
174	CAT-I	D13046	CLONIDINE TAB IP	100mcg	1 No	715
175	CAT-I	D13023	CLOPIDOGREL TAB IP	75 MG	1 No	668
176	CAT-I	D08038	CLOTRIMAZOLE CREAM IP	(2% w/w)	10gm Tube	584
177	CAT-I	D08039	CLOTRIMAZOLE CREAM IP	(1% w/w)	10gm Tube	584
178	CAT-I	D08021	CLOTRIMAZOLE MOUTH PAINT	1%	15 ml	660
179	CAT-I	D08008	CLOTRIMAZOLE VAGINAL PESSARIES IP	200 mg	1 No	584
180	CAT-I	D02006	CLOXACILLIN CAP IP	250 mg/ 500 mg	1 No	584
181	CAT-I	D02029	CLOXACILLIN INJ IP	500MG	IM/IV VIAL	1139
182	CAT-I	D02070	CLOXACILLIN SYRUP IP	125mg/5ml	60 ml bottle	584
183	CAT-I	D17014	CLOZAPINE TAB IP	25MG	1 No	751
184	CAT-I	D17015	CLOZAPINE TAB IP	100mg	1 No	751
185	CAT-I	D02002	CO-TRIMOXAZOLE ORAL SUSPENSION IP	40mg 200mg	50 ml Bottle	501
186	CAT-I	D02001	CO-TRIMOXAZOLE TAB IP	160mg+ 800mg	1 No	584
187	CAT-I	D03009/12	COUGH SYRUP	Each 5 ml contains: CPM-IP 2mg, Ammonium Chloride IP 100mg,Sodium Citrate IP 30mg,Menthol IP	50 ml Bottle	501
188	CAT-I	D03034	COUGH SYRUP	Each 5 ml contains: Ambroxol HCL- 15 mg, Guiphenesin- 50 mg , Terbutaline Sulphate- 1.25 mg , Menthol- 2.5 mg, Flavoured syrupy base q.s	50 ml Bottle	501
189	CAT-I	D15025	CYCLOPENTOLATE 1 % AND PHENYL EPHRINE 5 % OPHTHALMIC SOLUTION	1 % + 5 %	5 ml	660
190	CAT-I	D05021	DEFLAZACORT TAB	6mg	1 No	835
191	CAT-I	D05001	DEXAMETHASONE INJ IP	4 mg/ml	2 ml Vial	668
192	CAT-I	D05003	DEXAMETHASONE TAB IP	0.5 mg	1 No	668
193	CAT-I	D04024	DEXMEDITOMEDINE INJ	200 mcg/2ml	2 ml amp	715
194	CAT-I	D18003	DEXTROSE INJ IP	5%	500ml Bot	1503
195	CAT-I	D18004	DEXTROSE INJ IP	10%	500ml Bot	1503
196	CAT-I	D18006	DEXTROSE INJ IP	25%	100ml bottle	1503

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
197	CAT-I	D07007	DIAZEPAM INJ IP	5 mg/ml	2ml Amp.	1135
198	CAT-I	D17001	DIAZEPAM TAB IP	5mg	1 No	893
199	CAT-I	D01028	DICLOFENAC SODIUM GEL IP	1% w/w	25gm Tube	550
200	CAT-I	D01005	DICLOFENAC SODIUM INJ IP	25 mg/ml	3 ml amp	876
201	CAT-I	D01004	DICLOFENAC SODIUM TAB IP(GASTRO-RESISTANT)	50 mg.	1 No	484
202	CAT-I	D20009	DICYCLOMINE HCL INJ IP	10mg/ml	2ml Amp	1002
203	CAT-I	D20008	DICYCLOMINE HCL TAB IP	10 mg	1 No	584
204	CAT-I	D08003	DIETHYL CARBAMAZINE TAB IP	100 mg	1 No	484
205	CAT-I	D13015	DIGOXIN INJ IP	0.5mg/2 ml	2 ml	1670
206	CAT-I	D13014	DIGOXIN TAB IP	0.25 mg	1 No	1253
207	CAT-I	D13004	DILTIAZEM TAB IP	30 mg	1 No	1002
208	CAT-I	D13076	DILTIAZEM INJ IP	5mg/ml	5ml Vial	1620
209	CAT-I	D13017	DOBUTAMINE HCL INJ IP	50 mg/ml	5 ml Amp	1670
210	CAT-I	D20007/12	DOMPERIDONE TAB IP (FILM COATED)	10 mg	1 No	542
211	CAT-I	D13016	DOPAMINE HCL INJ IP	40 mg/ml	5 ml	1086
212	CAT-I	D15027	DORZOLAMIDE + TIMOLOL EYE DROPS IP	2 % + 0.5 %	5 ml	660
213	CAT-I	D15028	DORZOLAMIDE EYE DROPS IP	2%	5 ml	660
214	CAT-I	D02014/12	DOXYCYCLINE TAB USP	100 mg	1 No	1002
215	CAT-I	D18007/12	ELECTROLYTE P(MULTI ELECTROLYTE IN D 5%) INJ	500ml	Bottle	1753
216	CAT-I	D13032/12	ENALAPRIL MALEATE TAB IP(FILM COATED)	5 mg	1 No	835
217	CAT-I	D17029	ESCITALOPRAM TAB IP	10 mg	1 No	605
218	CAT-I	D03009	EXPECTORANT MIXTURE CONCENTRATED	Each 5ml contains: Camphorated Opium Tincture IP 66- 1.62 ml, Tincture Ipecacuanha IP 66 – 0.875 ml, Tincture Urgenia IP 66 - 0.75 ml, Aromatic Spirit of Ammonia IP 66 - 0.875 ml, Chloroform IP 0.025 ml, Water QS, Alcohol Content 40- 45% v/v.	500 ml Bottle	501
219	CAT-I	D22006	FERROUS SULPHATE TAB IP	200 mg	1 No	418
220	CAT-I	D08014	FLUCONAZOLE TAB IP	150 MG	1 No	601
221	CAT-I	D05037	FLUNARIZINE TAB	10mg	1 No	825

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
222	CAT-I	D15029	FLUOROMETHOLONE EYE DROPS IP	0.10%	5 ml	584
223	CAT-I	D17036	FLUOXETINE CAP IP	20 mg	1 No	726
224	CAT-I	D17013	FLUPHENAZINE DECANOATE INJ IP	25MG	1ML Amp	1753
225	CAT-I	D15030	FLURBIPROFEN EYE DROPS IP	0.03%	5 ml	584
226	CAT-I	D12002	FOLIC ACID TAB IP	5 mg	1 No	877
227	CAT-I	D19002	FRUSEMIDE INJ IP	10mg/ml	2ml Amp	877
228	CAT-I	D19001	FRUSEMIDE TAB IP	40mg	1 No	459
229	CAT-I	D14032	FUSIDIC ACID CREAM IP	2%	10gm tube	330
230	CAT-I	D07016	GABAPENTIN TAB IP	100mg	1 No	605
231	CAT-I	D14010	GAMMA BENZENE HEXA CHLORIDE SOLUTION	1%w/v	100ml Bottle	418
232	CAT-I	D02013	GENTAMICIN INJ IP	80 mg/2ml	IM/IV VIAL	1586
233	CAT-I	D15032	GENTAMICIN EYE DROPS IP	0.3% W/V	5 ml	1070
234	CAT-I	D21001	GLIBENCLAMIDE TAB IP	5mg	1 No	668
235	CAT-I	D21028	GLIMEPIRIDE TAB IP	1 mg	1 No	880
236	CAT-I	D21032/12	GLIMEPIRIDE TAB IP	2mg	1 No	880
237	CAT-I	D14029/12	GLYCERINE IP	100gm	bottle	330
238	CAT-I	D13047	GLYCERYL TRINITRATE TAB	2.6mg	1 No	619
239	CAT-I	D04019	GLYCOPYRROLATE INJ IP	0.2mg/ml	1ml Amp	1139
240	CAT-I	D17012	HALOPERIDOL INJ IP	5mg/ml	1ml Amp	1753
241	CAT-I	D17010	HALOPERIDOL TAB IP	5 mg	1 No	751
242	CAT-I	D17052	HALOPERIDOL TAB IP	1.5mg	1 No	1420
243	CAT-I	D12003	HEPARIN SODIUM INJ IP	5000 I U/ml	5 ml Vial	2088
244	CAT-I	D15034	HOMATROPINE EYE DROPS IP	2%	5 ml	584
245	CAT-I	D04025	HYALURONIDASE INJ IP	1500 IU	1 ml amp	1073
246	CAT-I	D19005	HYDROCHLOROTHIAZIDE TAB IP	25 mg	1 No	374
247	CAT-I	D05002	HYDROCORTISONE SODIUM SUCCINATE INJ IP	100 mg	Vial	1503
248	CAT-I	D08024	HYDROXY CHLOROQUINE TAB IP	200mg	1 No	660
249	CAT-I	D12006	HYDROXY ETHYL STARCH IV INFUSION 6%	130kDa/0.4	500 ml Bottle	935
250	CAT-I	D16013	HYDROXY PROGESTERONE INJ IP	250mg/ ml	1 ml Amp	616
251	CAT-I	D16024	HYDROXY PROGESTERONE INJ IP	250mg/ ml	2 ml Amp	616
252	CAT-I	D15035	HYDROXY PROPYL METHYL CELLULOSE EYE DROPS	0.30%	10 ml	451
253	CAT-I	D24108C	HYDROXY UREA CAP IP	500mg	1 No	550
254	CAT-I	D15036	HYDROXYPROPYL METHYL CELLULOSE EYE DROPS	2%	2 ml[PFS]	385
255	CAT-I	D20028	HYOSCINE BUTYLBROMIDE INJ IP	20mg/ml	1 ml amp	1020

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
256	CAT-I	D01051	KETOROLAC TROMETHAMINE INJ IP	30 mg/ml	1 ml amp	1620
257	CAT-I	D01016	IBUPROFEN TAB IP (FILM COATED)	400 mg	1 No	542
258	CAT-I	D17004	IMIPRAMINE TAB IP	25mg	1 No	526
259	CAT-I	D01031	INDOMETHACIN CAP IP	25mg	1 No	627
260	CAT-I	D23001	IOHEXOL INJ USP	350mg/ml	50ml	1837
261	CAT-I	D23007	IOHEXOL INJ USP	350mg/ml	100ml	1837
262	CAT-I	D03013	IPRATROPIUM NEBULISING SOLUTION	250mcg	15 ml	660
263	CAT-I	D22016	IRON SUCROSE INJ USP	(100mg elemental Iron/5ml) or (200mg elemental Iron/5ml)	5ml AMP	963
264	CAT-I	D22036	IRON SUCROSE INJ USP	20mg elemental Iron/ml)	10ml AMP	963
265	CAT-I	D04022	ISOFLURANE LIQUID	100ml	Bottle	440
266	CAT-I	D13002	ISOSORBIDE DINITRATE TAB IP	10 mg	1 No	835
267	CAT-I	D13049	ISOSORBIDE MONONITRATE TAB IP	20mg	1 No	835
268	CAT-I	D08026	IVERMECTIN TAB USP	6mg	1 No	990
269	CAT-I	D13051	LABETALOL TAB IP	100mg	1 No	668
270	CAT-I	D13063	LABETALOL INJ	20mg/ml	1ml Amp	620
271	CAT-I	D20015	LACTULOSE SOLUTION USP	667mg/ ml	100 ml	501
272	CAT-I	D07018	LEVETIRACETAM TAB IP	500mg	1 No	770
273	CAT-I	D02075	LEVOFLOXACIN TAB IP	500mg	1 No	880
274	CAT-I	D04018	LIGNOCAINE 2% WITH ADRENALINE INJ IP	1:200000	30 ml	1076
275	CAT-I	D04003	LIGNOCAINE HCL GEL IP	2%	30 gm Tube.	702
276	CAT-I	D04004	LIGNOCAINE HCL INJ IP (FOR IV USE)	2% w/v	30 ml Vial	684
277	CAT-I	D04038	LIGNCAINE HYDROCHLORIDE INJ IP (for IM use)	2%w/v	10ml Vial	1470
278	CAT-I	D02076	LINEZOLID INJ	200mg/100 ml	300 ml bottle	1337
279	CAT-I	D02078	LINEZOLID TAB IP	600mg	1 No	825
280	CAT-I	D14024	LIQUID PARAFFIN IP	100 ml	BOTTLE	363
281	CAT-I	D17025	LITHIUM CARBONATE TAB IP	300 mg	1 No	949
282	CAT-I	D17026	LITHIUM CARBONATE PROLONGED RELEASE TAB IP	400mg	1 No	863
283	CAT-I	D17033	LORAZEPAM TAB IP	2 mg	1 No	1012
284	CAT-I	D13011	LOSARTAN POTASSIUM TAB IP	25 mg	1 No	1211
285	CAT-I	D13053	LOSARTAN POTASSIUM TAB IP	50mg	1 No	1211

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
286	CAT-I	D12019	LOW MOLECULAR WEIGHT HEPARIN INJ IP	40mg/0.4 ml	VialPFS	7590
287	CAT-I	D16007	MAGNESIUM SULPHATE INJ IP	500mg/ml	2ml Amp	501
288	CAT-I	D14007	MAGNESIUM SULPHATE PASTE BP	500 Gram/ 100gm	Bottle	418
289	CAT-I	D14042	MAGNESIUM SULPHATE PASTE BP	100gm	Bottle	418
290	CAT-I	D18010	MANNITOL INJ IP	20%w/v	100 ml Bot	1503
291	CAT-I	D16016	MEDROXY PROGESTERONE ACETATE TAB IP	10mg	1 No	715
292	CAT-I	D01014	MEFENAMIC ACID TAB BP	500 mg	1 No	668
293	CAT-I	D02096	MEROPENAM INJ IP	1gm	Vial	2320
294	CAT-I	D21003	METFORMIN TAB IP	500mg	1 No	668
295	CAT-I	D13039	METHYL DOPA TAB IP	250mg	1 No	715
296	CAT-I	D05012	METHYL PREDNISOLONE SODIUM SUCCINATE INJ USP	500 mg	Vial	1670
297	CAT-I	D05028	METHYL PREDNISOLONE SODIUM SUCCINATE INJ USP	1gm	Vial	1670
298	CAT-I	D05013	METHYL PREDNISOLONE SODIUM SUCCINATE INJ USP	40 mg/ml	1 ml Amp	1002
299	CAT-I	D16004	METHYLERGOMETRIN MALEATE INJ IP	200mcg/ ml	1ml Amp	1169
300	CAT-I	D20005	METOCLOPRAMIDE INJ IP	5mg/ml	2ml Amp	1002
301	CAT-I	D20006	METOCLOPRAMIDE TAB IP	10mg	1 No	584
302	CAT-I	D13033	METOPROLOL TAB IP	50 MG	1 No	501
303	CAT-I	D02025	METRONIDAZOLE INJ IP	5 mg/ml	100ml bottle	1128
304	CAT-I	D02023	METRONIDAZOLE TAB IP	200 mg	1 No	351
305	CAT-I	D02024	METRONIDAZOLE TAB IP	400 mg	1 No	351
306	CAT-I	D02097	METRONIDAZOLE BENZOATE ORAL SUSPENSION IP	200mg/5ml	30ml bottle	200
307	CAT-I	D14041	MICONAZOLE CREAM IP	2% w/w	10gm Tube	1250
308	CAT-I	D07011	MIDAZOLAM INJ IP	1 mg/ml	5 ml Vial	715
309	CAT-I	D16017	MIFEPRISTONE TAB IP	200mg	1 No	770
310	CAT-I	D16026	MISOPROSTOL TAB IP	200mcg	1 No	1520

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
311	CAT-I	D20013	MIXTURE CARMINATIVE CONCENTRATE	EACH 10ML, CONTAINS:WEAK GINGER TINCTURE BP/IP-0.625ML, AROMATIC SPIRIT OF AMMONIA IP-0.625ML,PEPPERMINT SPIRIT BP-0.25ML, CHLOROFORM IP-0.019ML, SODIUM BICARBONATE IP-0.275 GM, COMPOUND CARDAMOM TINCTURE IP-3.0 ML, AQUA Q.S-10 ML, ALCOHOL CONTENT-20-26% V/V	500ml Bottle.	501
312		D01052	MORPHINE SULPHATE TAB (IMMEADIATE RELEASE) IP	10 mg	1 No	715
313		D01010	MORPHINE SULPHATE INJ IP	15 mg/ml	1 ml Amp	715
314	CAT-I	D15041	MOXIFLOXACIN EYE DROPS IP	0.50%	5 ml	584
315	CAT-I	D14035	MUPIROCIN OINTMENT IP	2%w/w	5gm tube	550
316	CAT-I	D06014	N-ACETYL CYSTEINE INJ	1g	5 ml amp	792
317	CAT-I	D06015	N-ACETYL CYSTEINE TAB	600mg	1 No	668
318	CAT-I	D15042	NATAMYCIN OPTHALMIC SUSPENSION IP	5%w/v	5ml	751
319	CAT-I	D06003	NALOXONE INJ IP	400 mcg/ml	1 ml Amp	1837
320	CAT-I	D16025	NATURAL MICRONISED PROGESTERONE SOFT GELATIN SR CAP	200mg	1 no	660
321	CAT-I	D13064	NEBIVOLOL TAB IP	5mg	1 No	1750
322	CAT-I	D15044	NEPAFENAC EYE DROPS	0.1%v/v	5ml	584
323	CAT-I	D04008	NEOSTIGMINE METHYL SULPHATE INJ IP	0.5 mg/ml	1 ml Amp	802
324	CAT-I	D13034	NIFEDIPINE PROLONGED-RELEASE TAB IP	20 mg	1 No	825
325	CAT-I	D13065	NIFEDIPINE PROLONGED-RELEASE TAB IP	10 mg	1 No	825
326	CAT-I	D17006	NITRAZEPAM TAB IP	5mg	1 No	584
327	CAT-I	D02080	NITROFURANTOIN TAB IP	100mg	1 No	485
328	CAT-I	D13028	NITROGLYCERIN INJ IP	25mg/5ml	Amp	1645
329	CAT-I	D29005	NORADRENALINE BITARTRATE INJ IP/USP	4mg/2ml	2 ml amp	468

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
330	CAT-I	D16020	NORETHISTERONE TAB IP	5mg	1 No	660
331	CAT-I	D02016	NORFLOXACIN TAB IP	400 mg	1 No	584
332	CAT-I	D15046	OFLOXACIN EAR/EYE DROPS	0.30%	10 ml	660
333	CAT-I	D02018	OFLOXACIN INFUSION IP	2 mg/ml	100ml bot	1837
334	CAT-I	D02017	OFLOXACIN TAB IP	200 mg	1 No	751
335	CAT-I	D17016	OLANZAPINE TAB IP	10 mg	1 No	726
336	CAT-I	D17020	OLANZAPINE TAB IP	5 mg	1 No	726
337	CAT-I	D20004/12	OMEPRAZOLE(GASTRO RESISTANT) CAP IP	20mg	1 No	1503
338	CAT-I	D20014	ONDANSETRON INJ IP	2mg/ml	2 ml Amp	1252
339	CAT-I	D20032	ONDANSETRON TAB IP	4mg	1 No	660
340	CAT-I	D20041	ONDANSETRON ORAL SOLUTION IP	2mg/5ml	30ml bottle	1670
341	CAT-I	D20011/12	ORS POWDER IP	Single dose sachet	20.5 gm Packet	751
342	CAT-I	D09007	OSELTAMIVIR CAP IP	75mg	1 No	880
343	CAT-I	D07019	OXCARBAZEPINE TAB IP	150mg	1 No	584
344	CAT-I	D20018	PANTOPRAZOLE INJ BP	40mg	10 ml Vial	715
345	CAT-I	D20033	PANTOPRAZOLE (GASTRO RESISTANT) TAB IP	40mg	1 No	303
346	CAT-I	D01035	PARACETAMOL INFUSION IP	1gm/100ml	100 ml bottle	668
347	CAT-I	D01009	PARACETAMOL INJ	150mg/2ml	2ml Amp.	668
348	CAT-I	D01003	PARACETAMOL PAEDIATRICS SYRUP/SUSPENSION IP	125mg/5ml	60ml Bottle	751
349	CAT-I	D01002	PARACETAMOL TAB IP	500 mg.	1 No	584
350	CAT-I	D02082	PENICILLIN V TAB IP	250mg	1 No	391
351	CAT-I	D29011	PERITONEAL DIALYSIS FLUID IP	1L	Bottle	1320
352	CAT-I	D05007	PHENIRAMINE MALEATE TAB IP	25 mg	1 No	735
353	CAT-I	D14036	PERMETHRIN CREAM	5%	30gm	660
354	CAT-I	D07003	PHENOBARBITONE SODIUM INJ IP	200mg/ml	1 ml Amp	835
355	CAT-I	D07001	PHENOBARBITONE TAB IP	30 mg	1 No	576
356	CAT-I	D07002	PHENOBARBITONE TAB IP	60 mg	1 No	576
357	CAT-I	D07025	PHENYTOIN ORAL SUSPENSION IP	25mg/ml	200 ml bottle	584
358	CAT-I	D07008	PHENYTOIN SODIUM INJ IP	50mg/ml	2ml amp	1086
359	CAT-I	D07004	PHENYTOIN SODIUM TAB IP	100 mg	1 No	584
360	CAT-I	D12005	PHYTOMENADIONE (VITAMIN K1) INJ IP	10 mg/ml	1 ml Amp	751
361	CAT-I	D15049	PILOCARPINE NITRATE EYE DROPS IP	2%	5 ml	751
362	CAT-I	D02039	PIPERACILLIN 4GM + TAZOBACTAM 500 MG INJ IP	4.5gm	Vial	880
363	CAT-I	D02083	PIPERACILLIN+ TAZOBACTAM INJ IP	2gm + 250mg	Vial	880

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
364	CAT-I	D18014	POTASSIUM CHLORIDE INJ IP	15% w/v	10ml Amp	743
365	CAT-I	D18015	POTASSIUM CITRATE SOLUTION	Potassium Citrate-1100 mg + Citric Acid-334 mg	200 ml	462
366	CAT-I	D18018	POTASSIUM CHLORIDE ORAL SOLUTION USP	10.00%	100 ML	743
367	CAT-I	D14008	POVIDONE IODINE OINTMENT USP	5%w/w	(25gm Tube)	293
368	CAT-I	D14043	POVIDONE IODINE OINTMENT USP	5%w/w	(10gm Tube)	293
369	CAT-I	D25004	POVIDONE IODINE SCRUB USP	7.50%	500ml Bottle	226
370	CAT-I	D14011	POVIDONE IODINE SOLUTION IP	5% w/v	500 ml Bottle	317
371	CAT-I	D15051	POVIDONE IODINE SOLUTION IP	5%	5 ml	317
372	CAT-I	D16006	POVIDONE IODINE VAGINAL PESSARIES	200 mg	1 No	317
373	CAT-I	D06004	PRALIDOXIME INJ IP	1 gm	Vial	1086
374	CAT-I	D13056	PRAZOSIN TAB(EXTENDED RELEASE)	5mg	1 No	677
375	CAT-I	D15052	PREDNISOLONE ACETATE EYE/EAR DROPS	1%	5 ml	751
376	CAT-I	D05033	PREDNISOLONE TAB IP	20mg	1 No	993
377	CAT-I	D05011	PREDNISOLONE TAB IP	10mg	1 No	993
378	CAT-I	D05034	PREDNISOLONE TAB IP	5mg	1 No	993
379	CAT-I	D17041	PROCHLORPERAZINE INJ IP	12.5mg/ml	1 ml amp	979
380	CAT-I	D17040	PROCHLORPERAZINE TAB IP	5 mg	1 No	688
381	CAT-I	D05009	PROMETHAZINE INJ IP	25 mg/ml	2ml Amp	710
382	CAT-I	D05015	PROMETHAZINE TAB IP	10 mg	1 No	495
383	CAT-I	D15053	PROPARACAINE HCL OPHTHALMIC SOLUTION	0.50%	5 ml	517
384	CAT-I	D04011	PROPOFOL INJ IP	1% w/v	50ml Vial	1670
385	CAT-I	D13030	PROPRANOLOL TAB IP	40 MG	1 No	517
386	CAT-I	D13029/12	PROPRANOLOL TAB IP	20 MG	1 No	517
387	CAT-I	D12012	PROTAMINE SULPHATE INJ IP	10 mg/ml	5 ml Amp	1753
388	CAT-I	D17022	QUETIAPINE TAB IP	50 mg	1 No	660
389	CAT-I	D17056	QUETIAPINE TAB IP	100mg	1 No	660
390	CAT-I	D08010	QUININE INJ IP	300 mg/ml	2 ml Amp	935
391	CAT-I	D08037	QUININE TAB IP	300mg	1 No	572
392	CAT-I	D20021	RABEPRAZOLE GASTRO RESISTANT TAB IP	20 mg	1 No	1750
393	CAT-I	D13059	RAMIPRIL TAB IP	5mg	1 No	1750
394	CAT-I	D20001	RANITIDINE HCL INJ IP	50mg /2ml	2ml Amp	1253
395	CAT-I	D20002	RANITIDINE HCL TAB IP	150mg	1 No	718
396	CAT-I	D18009	RINGERS LACTATE INJ IP	500ml	Bottle	1670
397	CAT-I	D17017	RISPERIDONE TAB USP	2 mg	1 No	584

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
398	CAT-I	D17037	RISPERIDONE TAB USP	1 mg	1 No	715
399	CAT-I	D03017	SALBUTAMOL INHALATION IP	100 mcg/puff	200 MD	605
400	CAT-I	D03006	SALBUTAMOL NEBULISER SOLUTION BP	5mg/ml.	10ml.	526
401	CAT-I	D03004	SALBUTAMOL SULPHATE TAB IP	4 mg	1 No	751
402	CAT-I	D03024	SALBUTAMOL SYRUP IP	2mg / 5ml	60ml Bottle	501
403	CAT-I	D14025	SALICYLIC ACID OINTMENT IP	10 % w/w,	20gm tube	605
404	CAT-I	D18016	SALINE INJ	3%	100ml	1045
405	CAT-I	D15011	SALINE NASAL DROPS	0.65 %w/v	15ml Bot	501
406	CAT-I	D01041	SERRATIOPEPTIDASE TAB IP	10mg	1 No	369
407	CAT-I	D17019	SERTRALINE TAB IP	50 mg	1 No	584
408	CAT-I	D14001	SILVER SULPHADIAZINE CREAM IP	1% w/w	100gm	459
409	CAT-I	D14001/12	SILVER SULPHADIAZINE CREAM IP	1% w/w	500gm	459
410	CAT-I	D14023/12	SISOMICIN CREAM	0.1 % w/w	10 gm tube	825
411	CAT-I	D15008	SODIUM BICARBONATE EAR DROPS BPC	10ML	Bottle	501
412	CAT-I	D04012	SODIUM BICARBONATE INJ IP	7.5% w/v	10ml Amp	668
413	CAT-I	D18002	SODIUM CHLORIDE & DEXTROSE INJ IP	0.9%+5%w/v	500ml Bottle	1503
414	CAT-I	D18001	SODIUM CHLORIDE INJ IP	0.9%w/v	500ml Bot	1503
415	CAT-I	D18017	SODIUM CHLORIDE INJ IP	0.009	100 ml	1503
416	CAT-I	D07021	SODIUM VALPROATE INJ IP	100mg/ml	5 ml vial	990
417	CAT-I	D07023	SODIUM VALPROATE ORAL SOLUTION IP	200mg/5ml	100 ml Bottle	448
418	CAT-I	D07006	SODIUM VALPROATE GASTRO RESISTANT TAB IP	200 mg	1 No	584
419	CAT-I	D07010	SODIUM VALPROATE GASTRO RESISTANT TAB IP	500 mg	1 No	584
420	CAT-I	D19003	SPIRONOLACTONE TAB IP	25mg	1 No	459
421	CAT-I	D20036	SUCRALFATE SUSPENSION	1g/5ml	100 ml bottle	770
422	CAT-I	D25002	SURGICAL SPIRIT IP	500ml	Bottle	501
423	CAT-I	D13061	TELMISARTAN TAB IP	40mg	1 No	668
424	CAT-I	D03007	TERBUTALINE INJ IP	0.5 mg/ml	1ml Amp	970
425	CAT-I	D22032	THIAMINE INJ IP	100 mg/ml	2ml	1220
426	CAT-I	D22033	THIAMINE TAB IP	100 mg	1 No	1120
427	CAT-I	D03001	THEOPHYLLINE AND ETOPHYLLINE INJ	50.6 mg+ 169.4 mg	2 ml Amp.	668
428	CAT-I	D03002	THEOPHYLLINE AND ETOPHYLLINE TAB	23 mg+ 77 mg	1 No	501
429	CAT-I	D04014	THIOPENTONE SODIUM INJ IP	0.5 Gram	Vial	1253
430	CAT-I	D21019	THYROXINE SODIUM TAB IP	100 mcg	1 No	1503
431	CAT-I	D21036	THYROXINE SODIUM TAB IP	50 mcg	1 No	1503

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
432	CAT-I	D15005	TIMOLOL MALEATE EYE DROPS IP	0.5%w/v	5ml/Bot	584
433	CAT-I	D15059	TOBRAMYCIN EYE OINTMENT USP	0.30%	5gm	517
434	CAT-I	D15066	TOBRAMYCIN EYE/EAR DROPS	0.3% v/v	5 ml bottle	584
435	CAT-I	D01011	TRAMADOL INJ	50MG/ML	1 ml Amp	1253
436	CAT-I	D01048	TRAMADOL PROLONGED RELEASE TAB	50MG/ 100MG	1 No	1002
437	CAT-I	D12015	TRANEXAMIC ACID INJ IP	500mg/5ml	5ml amp	935
438	CAT-I	D12014	TRANEXAMIC ACID TAB IP	500 mg	1 No	187
439	CAT-I	D11001	TRIHEXYPHENIDYL TAB IP	2mg	1 No	668
440	CAT-I	D17069	TRIFLUOPERAZINE TAB IP	5 mg	1 No	920
441	CAT-I	D15006	TROPICAMIDE EYE DROPS IP	1%w/v	5ml	620
442	CAT-I	D15060	TROPICAMIDE + PHENYLEPHRINE OPHTHALMIC SOLUTION	1% + 2.5%	5 ml	660
443	CAT-I	D14027/12	TURPENTINE LINIMENT IP	50 ml	bottle	330
444	CAT-I	D14027	TURPENTINE LINIMENT IP	100ml	bottle	330
445	CAT-I	D20037	URSODEOXYCHOLIC ACID TAB IP	300mg	1 No	880
446	CAT-I	D02027	VANCOMYCIN HYDROCHLORIDE IV INFUSION IP	500mg	Vial	1837
447	CAT-I	D04020	VECURONIUM BROMIDE INJ IP	4mg	Vial	1518
448	CAT-I	D04021	VECURONIUM BROMIDE INJ IP	10mg	Vial	1518
449	CAT-I	D13007/12	VERAPAMIL TAB IP	40mg	1 No	584
450	CAT-I	D22002/12	VITAMIN B COMPLEX (STRONG) TAB	Each Tablet Containing Nictonamide IP 20mg, Pyridoxine HCL IP 2 mg, Riboflavin IP 2 mg, Thiamine HCL IP 5 mg	1 No	501
451	CAT-I	D12001/12	VITAMIN B12/ CYANOCOBALAMIN INJ IP	100MCG/ml	2ml amp	810
452	CAT-I	D22020	VITAMIN C TAB IP	500mg	1 No	220

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
453	CAT-I	D22004/12	VITAMIN MULTI TAB(FILM COATED)	Each Tablet Containing Vitamin A-2500 iuVitamin-D 200 iuVitamin- B1 2mgVitamin-B2 2mg Vitamin B6 0.5 mgCalciumPantothenate-1mgNiacinamide-25mgVitamin-C 50mgFolic Acid-0.2mg	1 No	668
454	CAT-I	D21038	VOGLIBOSE TAB IP	0.2mg	1 No	990
455	CAT-I	D12013/12	WARFARIN SODIUM TAB IP	2mg	1 No	605
456	CAT-I	D12021	WARFARIN SODIUM TAB IP	5mg	1 No	605
457	CAT-I	D12020	WARFARIN SODIUM TAB IP	1mg	1 No	605
458	CAT-I	D18011	WATER FOR INJECTION IP	10 ml	Amp	1503
459	CAT-I	D14040	WHITE SOFT PARAFFIN IP	50gm	Bottle	418
460	CAT-I	D14005	WHITFIELDS OINTMENT IP	15 gm	Tube	418
461	CAT-I	D15009	XYLOMETAZOLINE NASAL DROPS IP	0.1% w/v	10 ml Bottle	501
462	CAT-I	D22024	ZINC SULPHATE DISPERSIBLE TAB IP	20mg elemental Zinc	1 No	220
463	CAT-I	D17059	ZOLPIDEM TAB IP	10mg	1 No	990
464	CAT-III	S27009	BLOOD ADMINISTRATION SET WITH MICROAGREGATE FILTER	Ml	1 No	1470
465	CAT-III	S27014	BP BLADE	SIZE -10	1 NO	1253
466	CAT-III	S27015	BP BLADE	SIZE -11	1 NO	1253
467	CAT-III	S27016	BP BLADE	SIZE -15	1 NO	1253
468	CAT-III	S27017	BP BLADE	SIZE -20	1 NO	1253
469	CAT-III	S27019	BP BLADE	SIZE -22	1 NO	1253
470	CAT-III	S27026	DISPOSABLE NEEDLE	20 G	1 No	1503
471	CAT-III	S27028	DISPOSABLE NEEDLE	22 G	1 No	1503
472	CAT-III	S27029	DISPOSABLE NEEDLE	23 G	1 No	1503
473	CAT-III	S27030	DISPOSABLE NEEDLE	24 G	1 No	1503
474	CAT-III	S27239	DISPOSABLE SYRINGE WITH FIXED NEEDLE 29 G (1ML GRADUATED)	1ml	1 NO	2157
475	CAT-III	S27031	DISPOSABLE SYRINGE WITHOUT NEEDLE	2 Cc	1 No	1253
476	CAT-III	S27032	DISPOSABLE SYRINGE WITHOUT NEEDLE	5 Cc	1 No	1253
477	CAT-III	S27033	DISPOSABLE SYRINGE WITHOUT NEEDLE	10 Cc	1 No	1253
478	CAT-III	S27039	DISPOSABLE THREE WAY STOPCOCK	1 Unit	1 No	1503

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
479	CAT-III	S27045	ENDOTRACHEAL TUBE 2.5	1 Unit	1 No	1503
480	CAT-III	S27046	ENDOTRACHEAL TUBE 3.0	1 Unit	1 No	1503
481	CAT-III	S27047	ENDOTRACHEAL TUBE 3.5	1 Unit	1 No	1503
482	CAT-III	S27048	ENDOTRACHEAL TUBE 4.0	1 Unit	1 No	1503
483	CAT-III	S27049	ENDOTRACHEAL TUBE 4.5	1 Unit	1 No	1503
484	CAT-III	S27050	ENDOTRACHEAL TUBE 5.0	1 Unit	1 No	1503
485	CAT-III	S27051	ENDOTRACHEAL TUBE 5.5	1 Unit	1 No	1503
486	CAT-III	S27054	ENDOTRACHEAL TUBE 5.5 WITH CUFF	1 Unit	1 No	1503
487	CAT-III	S27052	ENDOTRACHEAL TUBE 6.0	1 Unit	1 No	1503
488	CAT-III	S27055	ENDOTRACHEAL TUBE 6.0 WITH CUFF	1 Unit	1 No	1503
489	CAT-III	S27053	ENDOTRACHEAL TUBE 6.5	1 Unit	1 No	1503
490	CAT-III	S27056	ENDOTRACHEAL TUBE 6.5 WITH CUFF	1 Unit	1 No	1503
491	CAT-III	S27057	ENDOTRACHEAL TUBE 7.0 WITH CUFF	1 Unit	1 No	1503
492	CAT-III	S27058	ENDOTRACHEAL TUBE 7.5 WITH CUFF	1 Unit	1 No	1503
493	CAT-III	S27059	ENDOTRACHEAL TUBE 8.0 WITH CUFF	1 Unit	1 No	1503
494	CAT-III	S27060	ENDOTRACHEAL TUBE 8.5 WITH CUFF	1 Unit	1 No	1503
495	CAT-III	S27061	ENDOTRACHEAL TUBE 9.0 WITH CUFF	1 Unit	1 No	1503
496	CAT-III	S27222	EPIDURAL SET WITH LOR SYRINGE & FILTER	18 G	1 No	1320
497	CAT-III	S27062	FOLLEYS CATHETER	SIZE 12 F X 10 ML	1 No	1503
498	CAT-III	S27063	FOLLEYS CATHETER	SIZE 16F X 30 ML	1 No	1503
499	CAT-III	S27064	FOLLEYS CATHETER	SIZE 18 F X 30 ML	1 No	1503
500	CAT-III	S27067	FOLLEYS CATHETER	SIZE 10 F X 10 ML	1 No	1503
501	CAT-III	S27193	FOLLEYS CATHETER	SIZE 14 F X 30 ML	1 No	1366
502	CAT-III	S27038	I.V. CANNULA	24 G	1 No	1503
503	CAT-III	S27034	I.V. CANNULA WITH INJECTION PORT	16 G	1 No	1503
504	CAT-III	S27035	I.V. CANNULA WITH INJECTION PORT	18 G	1 No	1503
505	CAT-III	S27036	I.V. CANNULA WITH INJECTION PORT	20 G	1 No	1503
506	CAT-III	S27037	I.V. CANNULA WITH INJECTION PORT	22 G	1 No	1503
507	CAT-III	S27246	I.V. SET WITH 22G NEEDLE	1 Unit	1 No	1503

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
508	CAT-III	S27069	INFANT FEEDING TUBE	SIZE 4F	1 No	1503
509	CAT-III	S27070	INFANT FEEDING TUBE	SIZE 10F	1 No	1503
510	CAT-III	S27071	INFANT FEEDING TUBE	SIZE 5F	1 No	1503
511	CAT-III	S27072	INFANT FEEDING TUBE	SIZE 6F	1 No	1503
512	CAT-III	S27073	INFANT FEEDING TUBE	SIZE 8F	1 No	1503
513	CAT-III	S27221	NELATON CATHETER	SIZE 12	1 No	1320
514	CAT-III	S27076	RYLES TUBE	SIZE 10 F	1 No	1503
515	CAT-III	S27077	RYLES TUBE	SIZE 12 F	1 No	1503
516	CAT-III	S27079	RYLES TUBE	SIZE 16 F	1 No	1503
517	CAT-III	S27250	SICS BLADE (CRESANT)	2.5mm/2.6mm angeled level up	1No	1139
518	CAT-III	S27251	SICS BLADE (KERATOME)	2.8mm angeled level up	1No	1139
519	CAT-III	S27252	SICS BLADE (SIDE PORT)	15° STRAIGHT LANCE TIP	1No	1139
520	CAT-III	S27041	SPINAL NEEDLE	SIZE 23 G	1 No	1503
521	CAT-III	S27238	SPINAL NEEDLE	SIZE 25 G	1 No	1503
522	CAT-III	S27089	SUCTION CATHETER	SIZE – 10	1 No	1503
523	CAT-III	S27090	SUCTION CATHETER	SIZE – 12	1 No	1503
524	CAT-III	S27091	SUCTION CATHETER	SIZE – 14	1 No	1503
525	CAT-III	S27092	SUCTION CATHETER	SIZE – 6	1 No	1503
526	CAT-III	S27093	SUCTION CATHETER	SIZE – 8	1 No	1503
527	CAT-III	S27233	UMBILICAL CORD CLAMP	-	1 No	1253
528	CAT-III	S27095	URINE COLLECTING BAG WITH VALVE OUTLET	2 LITRE	1 No	2505
529	CAT-III	S27068	VACUSUCK SET (MOULDED TRANSPARENT HAVING NO JOINTS ON THE SURFACE OF THE TUBING)	2.5 M	1 No	1503
530	CAT-IV	S27010	BLOOD COLLECTION SINGLE BAG	350 ML	1 NO	1320
531	CAT-IV	D26006	MALARIA ANTIGEN DETECTING CARD	1TEST	1 No	1670
532	CAT-V	S27231/12	ABSORBANT COTTON GAUZE SCH.F(II)	100 CmX 20 M	Packet	584
533	CAT-V	S27007	ABSORBANT COTTON WOOL IP	500gm Net	Packet	501
534	CAT-V	S27002	ADHESIVE TAPE U.S.P	10 cm X 5 mtr	Roll	1002
535	CAT-V	S27099	DISPOSABLE SURGEONS CAP - FEMALE	1 Unit	1 No	1002
536	CAT-V	S27098	DISPOSABLE SURGEONS CAP - MALE	1 Unit	1 No	1002
537	CAT-V	S27100	DISPOSABLE SURGEONS MASK (DOUBLE LAYER WITH TYING STRAP)	1 Unit	1 No	1002
538	CAT-V	S27194	ECG GEL	250 GM	BOTTLE	1265

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
539	CAT-V	S27085	GLOVES SURGICAL RUBBER (ISI)- Non Sterile	SIZE 6”	Pair	1503
540	CAT-V	S27086	GLOVES SURGICAL RUBBER (ISI)- Non Sterile	SIZE 6.5”	Pair	1503
541	CAT-V	S27087	GLOVES SURGICAL RUBBER (ISI)- Non Sterile	SIZE 7”	Pair	1503
542	CAT-V	S27088	GLOVES SURGICAL RUBBER (ISI)- Non Sterile	SIZE 7.5”	Pair	1503
543	CAT-V	S27196	GLOVES SURGICAL RUBBER - STERILE (ISI)	SIZE 6"	Pair	1503
544	CAT-V	S27197	GLOVES SURGICAL RUBBER - STERILE (ISI)	SIZE 6.5"	Pair	1503
545	CAT-V	S27198	GLOVES SURGICAL RUBBER - STERILE (ISI)	SIZE 7"	Pair	1503
546	CAT-V	S27199	GLOVES SURGICAL RUBBER - STERILE (ISI)	SIZE 7.5"	Pair	1503
547	CAT-V	S27003	HYPO ALLERGIC ACRYLIC PAPER TAPE	2.5cm X 9.1 mtr	Roll	993
548	CAT-V	S27230	PLASTER OF PARIS BANDAGE BP	10 cm X 2.7 mtr	Roll	668
549	CAT-V	S27001	PLASTER OF PARIS BANDAGES B.P	15 cm X 2.7 mtr	ROLL	668
550	CAT-V	S27075	RUBBER SHEET MACKINTHOSH	1 mtr	1 No	1503
551	CAT-VI	D25012	BLACK DISINFECTANT FLUID (GRIII RWC 5-7) BIS LOTION	5 Litre	Can	584
552	CAT-VI	D25011	BLEACHING POWDER	30%	1 kg Packet	334
553	CAT-VI	D25010	CHLORHEXIDINE GLUCONATE 2.5% V/V + ETHYL ALCOHOL 70% V/V SOLUTION	200 ml	Bottle	835
554	CAT-VI	D25006	CHLOROXYLENOL SOLUTION IP	5%	5 Lit Can	584
555	CAT-VI	D25014	FORMALDEHYDE SOLUTION IP	37% w/v	450 ml Bottle	418
556	CAT-VI	D25007	GLUTERALDEHYDE SOLUTION(WITHOUT SURFACTANT)	2%	5 Litre Can	501
557	CAT-VI	D25003/12	HYDROGEN PEROXIDE SOLUTION IP	20 Vol	1ltr. Bottle	317
558	CAT-VI	D25008	ORTHO-PHTHALALDEHYDE LOTION	0.55%	5 Ltr Can	501
559	CAT-VI	D25013	WASHING SODA	1 Kg	Packet	501
560	CAT-VII	S27505	BLACK SILK 5-0 1/2 CIRCLE ,TAPER CUT NEEDLE 17MM , 70- 90 CM	1 Foil	1 No	1253
561	CAT-VII	S27508/12	BRAIDED POLYGLYCOLIC ACID SUTURE 3-0, 40- 50CM, 3/8 CIRCLE CUTTING 12MM NEEDLE	1 Foil	1 No	1253

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
562	CAT-VII	S27509	BRAIDED POLYGLYCOLIC ACID SUTURE 5-0, 45CM, 3/8 CIRCLE REVERSE CUTTING 12MM NEEDLE	1 Foil	1 No	1253
563	CAT-VII	S27510	BRAIDED POLYGLYCOLIC ACID SUTURE 6-0, 45CM, 3/8 CIRCLE REVERSE CUTTING 12MM NEEDLE	1 Foil	1 No	1253
564	CAT-VII	S27517	CATGUT NO.1/0 RB 34-40 MM NEEDLE, 70-90 CM	1 Foil	1 No	1253
565	CAT-VII	S27519	MONOFILAMENT POLYAMIDE 10-0, 1/2 CIRCLE Micropoint Spatulated DOUBLE NEEDLE 6MM,30-40 CM	1 Foil	1 No	1253
566	CAT-VII	S27520/12	MONOFILAMENT POLYAMIDE 2-0,30-36MM, 3/8 CIRCLE CUTTING NEEDLE, 70-90CM	1 Foil	1 No	1253
567	CAT-VII	S27523/12	MONOFILAMENT POLYAMIDE 3-0,30-36MM,3/8 CIRCLE CUTTING NEEDLE,70-90CM	1 Foil	1 No	1253
568	CAT-VII	S27524/12	MONOFILAMENT Black POLYAMIDE 8/0, 3/8 CIRCLE REVERSE CUTTING MICRO POINT SPatulated 8MM, 30-40CM	1 Foil	1 No	1253
569	CAT-VII	S27525	MONOFILAMENT POLYPROPYLENE BLUE 1, 70-90CM 1/2 CRB (HEAVY) 40MM	1 Foil	1 No	1253
570	CAT-VII	S27526	MONOFILAMENT POLYPROPYLENE BLUE 1-0, 70-90CM 1/2 CRB 30MM	1 Foil	1 No	1253
571	CAT-VII	S27533	POLYDIOXANONE OF SIZE 1 WITH ½ CIRCLE RB, 45- 50MM HEAVY NEEDLE SUTURE LENGTH 1.5 M,FOR SHEATH CLOSURE	1 Foil	1 No	1253
572	CAT-VII	S27535	POLYGLACTIN 910 4-0,ROUND BODY NEEDLE 3/8 CIRCLE , 20MM,70-90 CM	1 Foil	1 No	1253
573	CAT-VII	S27536	POLYGLACTIN 910 OF SIZE 1,1/2 CIRCLE ROUND BODY NEEDLE,35-40 MM ,70-90 CM	1 Foil	1 No	1253
574	CAT-VII	S27537	POLYGLACTIN 910 OF SIZE 1-0,1/2 CIRCLE ROUND BODY 30- 36MM,70-90 CM	1 Foil	1 No	1253
575	CAT-VII	S27538	POLYGLACTIN 910,SIZE 2-0,1/2 CRB,30MM NEEDLE ,70-90CM	1 Foil	1 No	1253
576	CAT-VII	S27539	POLYGLACTIN 910,SIZE 3-0,1/2 CRB,26-30MM NEEDLE ,70-90CM	1 Foil	1 No	1253

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
577	CAT-VII	S27547	POLYGLYCOLIC ACID SIZE 6/0 , 3/8 REVERSE CUTTING, 8MM,DOUBLE NEEDLE,70-90 CM	1 Foil	1 No	1253
578	CAT-VII	S27549	POLYPROPYLENE 2-0, 1/2 CRB 26-30MM NEEDLE ,70-90 CM	1 Foil	1 No	1253
579	CAT-VII	S27550	POLYPROPYLENE 3-0, 1/2 CRB 24-26MM NEEDLE, 70-90 CM	1 Foil	1 No	1253
580	CAT-VII	S27553	POLYPROPYLENE 5-0, 3/8 ROUND BODY 12MM NEEDLE ,70-90 CM	1 Foil	1 No	1253
581	CAT-VII	S27555	MONOFILAMENT BLUE POLYPROPYLENE 6-0, 3/8 CIRCLE TAPER CUT, DOUBLE ARMED NEEDLE,13MM,70-90 CM	1 Foil	1 No	1253
582	CAT-VII	S27557	POLYPROPYLENE MESH 0.02 THICKNESS WITH 1.9KG BURST STRENGTH PER SQUARE CM HERNIA REPAIR	15x15 Cm	1 No	1253
583	CAT-VII	S27559/12	POLYPROPYLENE MESH 0.02 THICKNESS WITH 1.9KG BURST STRENGTH PER SQUARE CM HERNIA REPAIR	7X15 cm	1 No	1253
584	CAT-VII	S27561/12	SURGICAL SILK 2-0, 1/2 CIRCLE CUTTING NEEDLE 30MM,70-90 CM	1 Foil	1 No	1253
585	CAT-VII	S27564	SURGICAL SILK 4-0, 1/2 CIRCLE TAPERCUT NEEDLE 17MM,70-90 CM	1 Foil	1 No	1253
586	CAT-VII	S27565	SUTURE PACK SILK No. 1, 2X70-90 CM	1 Foil	1 No	1253
587	CAT-VII	S27568	SUTURE PACK SILK No. 2-0, 2X70-90 CM	1 Foil	1 No	1253
588	SPL	D14044	ACITRETIN CAP IP	25 mg	1 No	1870
589	SPL	D17063	AMISULPRIDE TAB IP	100 mg	1 No	1765
590	SPL	D13069	ATORVASTATIN TAB IP	40 mg	1 No	2250
591	SPL	D23006	BARIUM SULPHATE SUSPENSION BP	95% w/v	500 ml Bottle	190
592	SPL	D05038	BROMHEXINE TAB IP	8 MG	1 No	835
593	SPL	D04031	BUPIVACAINE INJ IP	0.005	20 ml vial	1670
594	SPL	D01050	BUPRENORPHINE INJ IP	0.3mg/ml	1 ml	570
595	SPL	D21045	CARBIMAZOLE TAB IP	5 mg	1 No	1170
596	SPL	D02100	CEFTAZIDIME INJ IP	1 gm	Vial	2100
597	SPL	D13073	CILOSTAZOL TAB IP	50 mg	1 No	1265
598	SPL	D02065	CLARITHROMYCIN TAB IP	500mg	1 No	
599	SPL	D02087	CLINDAMYCIN CAP IP	300 mg	1 No	1745
600	SPL	D02103	COLISTIMETHATE INJ IP	3 miu	Vial	1290
601	SPL	D32000	CYCLOSPORINE CAP IP	100 mg	1 No	1390
602	SPL	D06018	D-PENICILLAMINE TAB IP	250 mg	1 No	785

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
603	SPL	D10001	DAPSONE TAB IP	100 mg	1 No	765
604	SPL	D13075	DIGOXIN PAEDIATRIC SOLUTION IP	50mcg/ml	60 ml bottle	270
605	SPL	D07028	DIVALPROEX SODIUM PROLONGED RELEASE TAB IP	500mg	1 No	1350
606	SPL	D16027	DYDROGESTERONE TAB IP	10 MG	1 No	1670
607	SPL	D05022	FEXOFENADINE TAB IP	120mg	1 No	1765
608	SPL	D21049	FINASTERIDE TAB IP	5 MG	1 No	2250
609	SPL	D17008	FLUOXETINE CAP IP	10mg	1 No	1420
610	SPL	D17067	FLUVOXAMINE TAB IP	100 mg	1 No	1415
611	SPL	D05040	HYDROCORTISONE CREAM IP	0.01	15 gm	650
612	SPL	D16013	HYDROXY PROGESTERONE CAPROATE INJ IP	250mg/ ml	1 ml Amp	450
613	SPL	D05025	HYDROXYZINE TAB IP	10mg	1 No	1765
614	SPL	D02106	LEVOFLOXACIN INFUSION IP	500 mg	100 mL BOTTLE	1120
615	SPL	D04004	LIGNOCAINE HCL INJ IP	2% w/v	30 ml Vial	420
616	SPL	D12035	MEPHENTERMINE INJ IP	30 MG/ml	10 mL vial	320
617	SPL	D05041	METHYLPREDNISOLONE TAB IP	8 mg	1 No	1900
618	SPL	D13083	METOPROLOL INJ IP	1mg/ml	5ml Amp	1320
619	SPL	D16033	MISOPROSTOL TAB IP	100 mcg	1 No	1520
620	SPL	D16034	MISOPROSTOL TAB IP	25 mcg	1 No	1520
621	SPL	D14051	MOMETASONE FUROATE OINTMENT IP	0.1%W/W	10 gm tube	650
622	SPL	D05029	MONTELUKAST TAB IP	10mg	1 No	1765
623	SPL	D01052	MORPHINE SULPHATE TAB (IMMEADIATE RELEASE) IP	10 mg	1 No	715
624	SPL	D01033	NAPROXEN TAB IP	500mg	1 No	815
625	SPL	D13084	NICORANDIL TAB IP	5mg	1 No	1950
626	SPL	D07031	OXCARBAZEPINE TAB IP	300 mg	1 No	1365
627	SPL	D29006	PHENYLEPHRINE INJ IP	10mg/ml	1 ml Amp	1170
628	SPL	D21027	PIOGLITAZONE TAB IP	15 mg	1 No	1515
629	SPL	D08041	PRIMAQUINE TAB	7.5 mg	1 No	1450
630	SPL	D20051	RACECADOTRIL CAP IP	100 mg	1 No	1770
631	SPL	D13094	ROSUVASTATIN TAB IP	10mg	1 No	2250
632	SPL	D14055	SALICYLIC ACID OINTMENT IP	0.06	10gm tube	150
633	SPL	D21054	SILDENAFIL TAB IP	25 mg	1 No	1765
634	SPL	D03031	SALMETEROL AND FLUTICASONE PROPIONATE POWDER FOR INHALATION IP	200MCG + 125MCG Rotacap	1 No	1000
635	SPL	D18019	SODIUM CHLORIDE AND DEXTROSE INJ IP	0.45% + 5%	500ml bottle	1070
636	SPL	D13025	SODIUM NITROPRUSIDE INJ IP	50 MG	Vial	800

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Pre- fixed testing rate (Rs.)
637	SPL	D03033	TIOTROPIUM BROMIDE INHALER IP	9mcg	120 MD	1000
638	SPL	D07032	TOPIRAMATE TAB IP	50 mg	1 No	1415
639	SPL	D01055	TRIAMCINOLONE ACETONIDE (PRESERVATIVE FREE) INJ IP	40mg/ml	1ml	1250
640	SPL	D17058	TRICLOFOS ORAL SOLUTION IP	100mg/ml	30 ml bottle	200
641	SPL	D19011	VASOPRESSIN INJ IP	20 UNITS/ML	1ml	1620
642	SPL	D13093	VERAPAMIL INJ IP	2.5mg/ml	2ml	1570
643	SPL	D21039	VOGLIBOSE TAB IP	0.3mg	1 No	1170

List of items with no lab rates for testing are to be offered

APPENDIX I B

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Offered Rate (Rs.)
1	CAT-I	D02048	AMOXYCILLIN + POTASSIUM CLAVULANATE ORAL SUSPENSION	400MG+57MG	30ml bottle	
2	CAT-I	D02092	AMOXYCILLIN + POTASSIUM CLAVULANATE DROPS	80mg + 11.4mg	10ml bottle	
3	CAT-I	D15019	BIMATOPROST EYE DROPS	0.03%	3 ml	
4	CAT-I	D03025	BUDESONIDE NEBULISING SOLUTION	0.5mg/ml	2ml respules	
5	CAT-I	D03022	BUDESONIDE INHALER	100mcg/puff	200MD	
6	CAT-I	D22025	CALCIUM CARBONATE +VITAMIN D3 SUSPENSION	200mg + 200IU	100ml bottle	
7	CAT-I	D12029	CALCIUM DOBESILATE CAP	500mg	1 No	
8	CAT-I	D15069	DEXAMETHASONE EYE DROPS BP	0.10%	5ml	
9	CAT-I	D02095	CEFUROXIME AXETIL ORAL SUSPENSION BP	125mg/5ml	30ml bottle	
10	CAT-I	D12007	DEXTRAN 40 IN SODIUM CHLORIDE INJ USP	Low molecular wet Dextran 10% in Sodium Chloride Inj	500ml Bottle	
11	CAT-I	D20039	DOXYLAMINE SUCCINATE TAB USP	5mg	1 No	
12	CAT-I	D08030	KETOCONAZOLE CREAM BP	0.02	5gm tube	
13	CAT-I	D07027	LEVITERACETAM INJ	100mg/ml	Amp	
14	CAT-I	D03014	LEVOSALBUTAMOL INHALATION SOLUTION	0.63mg/3ml respules	1no	
15	CAT-I	D02086	METRONIDAZOLE GEL IP	0.01	25gm tube	
16	CAT-I	D15070	MOXIFLOXACIN EYE OINTMENT	5%w/w	5 gm tube	
17	CAT-I	D13086	NITROGLYCERINE TAB	2.6 mg	1 No	
18	CAT-I	D15071	OXYMETAZOLINE HYDROCHLORIDE NASAL SOLUTION (PAEDIATRIC)IP	0.025% w/v	10 ml	
19	CAT-I	D02108	PENICILIN G POTASSIUM TAB USP	400 mg	1 NO	
20	CAT-I	D01046	PIROXICAM TAB IP	20mg	1 No	
21	CAT-I	D01053	PREGABALIN TAB	75 mg	1no	
22	CAT-I	D15056	SODIUM CHLORIDE EYE DROPS BP	0.05	5ml	
23	CAT-I	D20040	SODIUM PHOSPHATE ENEMA BP	Sodium Dihydrogen Phosphate Dihydrate IP 10%w/v + Disodium Hydrogen Phosphate Dodecahydrate IP 8%w/v	100ml	

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Offered Rate (Rs.)
24	CAT-I	D22026	VITAMIN D3 DROPS BP	400IU/ml	15ml	
25	CAT-III	S27254	DISPOSABLE NEEDLE	26 G	1 No	
26	CAT-III	S27247	DISPOSABLE CVP CATHETER DOUBLE LUMEN (SELDINGER TECHNIQUE)	5F	1No	
27	CAT-III	S27248	DISPOSABLE CVP CATHETER DOUBLE LUMEN (SELDINGER TECHNIQUE)	7F	1No	
28	CAT-III	S27256	DISPOSABLE CVP CATHETER TRIPPLE LUMEN (SELDINGER TECHNIQUE)	7F	1No	
29	CAT-III	S27255	DISPOSABLE CVP CATHETER DOUBLE LUMEN (SELDINGER TECHNIQUE)	5F	1No	
30	CAT-IV	D26002	ANTI A MONOCLONAL IgM TITRE VALUE 512 (MINIMUM) SOLUTION	10ml	Bottle	
31	CAT-IV	D26003	ANTI AB MONOCLONAL IgM TITRE VALUE 512 (MINIMUM)SOLUTION	10 ML	Bottle	
32	CAT-IV	D26004	ANTI B MONOCLONAL IgM TITRE VALUE 512 (MINIMUM) SOLUTION	10ml	Bottle	
33	CAT-IV	D26005	ANTI D MONOCLONAL IgM TITRE VALUE 512 SOLUTION	10ML	Bottle	
34	CAT-IV	D26030	ANTI HUMAN GLOBULIN SERUM (COOMBS SERUM) POLY SPECIFIC (IgG + C3d)	5ml	Vial	
35	CAT-IV	D26011	ANTI HUMAN SERUM (LISS COOMBS FOR GEL TECHNOLOGY-GEL CARD&SOLUTION)	NULL	Bottle	
36	CAT-IV	S27253	BLOOD COLLECTION TRIPLE BAG	Sterile collapsible non-vented bags made up of DEHP plasticized PVC. Primary bag - 350ml,with CPDA 1 (49ml) First Satelite bag - 300ml Second Satelite bag – 300ml for platelet storage for 5 days Slits on both sides of the bags. Flexible non-kinking transparent tubings. Needle -16G straight sharp regular margins ultrathin walled and bevelled tips.	1 No	

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Offered Rate (Rs.)
37	CAT-IV	D26014	DENGUE IgM CAPTURE ELISA (1,2,3,4) KIT	1TEST	1 No	
38	CAT-IV	D26026	DENGUE LATEX AGGLUTINATION TEST KIT(RAPID METHOD)	1TEST	1 No	
39	CAT-IV	D26024	FOURTH GENERATION ELISA KIT FOR DETECTION OF P24 ANTIGEN AND ANTIBODY TO HIV 1&2	1TEST	1No	
40	CAT-IV	D26022	HEPATITIS B SURFACE ANTIGEN SCREENING KIT-EISA TEST KIT	1 Test	1 No	
41	CAT-IV	D26023	HEPATITIS B SURFACE ANTIGEN SCREENING KIT-EIA VISUAL ASSAY TEST	1 Test	1 No	
42	CAT-IV	D26017	HEPATITIS C ANTIBODY SCREENING-ELISA TEST KIT	1TEST	1No	
43	CAT-IV	D26016	HEPATITS C ANTIBODY SCREENING KIT - EIA VISUAL ASSAY(RAPID METHOD)	1TEST	1 No	
44	CAT-IV	D26019	HIV 1 & 2 ANTIBODY SCREENING EIA VISUAL ASSAY(RAPID METHOD)	1TEST	1 No	
45	CAT-IV	D26031	RPR CARD TEST FOR SYPHILIS	1 Test	1No	
46	CAT-IV	D26018	HIV 1 & 2 ANTIBODY SCREENING -ELISA TEST KIT	1 Test	1No	
47	CAT-V	S27219	ECG ELECTRODES	NULL	1 No	
48	CAT-VII	S27529	POLIGLECAPRONE 25, UNDYED, SIZE 3/0 WITH 3/8 CIRCLE	1 Foil	1 No	
49	CAT-VII	S27531	POLIGLECAPRONE 25, UNDYED, SIZE 5/0 WITH 3/8 CIRCLE CUTTING / REVERSE CUTTING NEEDLE 12-15 MM,70-90 CM	1 Foil	1 No	
50	CAT-VII	S27575	MONOFILAMENT BLACK POLYAMIDE 8-0,3/8 CIRCLE REVERSE CUTTING MICRO POINT SPATULATED 8MM,30-40CM	1Foil	1No	
51	CAT-VII	S27576	MONOFILAMENT BLUE POLYPROPYLENE 6-0,3/8 CIRCLE TAPER CUT,DOUBLE ARMED, 13MM,70-90CM	1Foil	1No	
52	CAT-VII	S27577	MONOFILAMENT POLYAMIDE 10-0,1/2 CIRCLE MICRO POINT SPATULATED DOUBLE NEEDLE 6MM,30-40CM	1Foil	1No	
53	CAT-VII	S27529	POLIGLECAPRONE 25,UNDYED,SIZE 3/0 WITH 3/8 CIRCLE CUTTING/REVERSE CUTTING NEEDLE 24-28MM,70-90CM	1Foil	1No	
54	CAT-VII	S27531	POLIGLECAPRONE 25,UNDYED,SIZE 5/0 WITH 3/8 CIRCLE CUTTING/REVERSE CUTTING NEEDLE 12-15MM,70-90CM	1Foil	1No	

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Offered Rate (Rs.)
55	CAT-VII	S27578	POLYGLYCOLIC ACID SIZE 6/0,3/8 REVERSE CUTTING 8MM DOUBLE NEEDLE,70-90CM	1Foil	1No	
56	CAT-VIII	X01014	X-RAY FILM FIXER	Powder to make 13.5 litres	1No	
57	CAT-VIII	X01012	X- RAY DEVELOPER LIQUID	19.5/Lit.	Packet	
58	CAT-VIII	X01010	X- RAY DEVELOPER POWDER	Powder to make 22.5 litres	Pkts	
59	CAT-VIII	X01011	X- RAY FIXER LIQUID	19.5/Lit.	Packet	
60	CAT-VIII	X01009	X- RAY FIXER POWDER	Powder to make 22.5 litres	Pkts	
61	CAT-VIII	X01013	X-RAY FILM DEVELOPER	Powder To Make 13.5 Litres	Packet	
62	CAT-VIII	X01001	X-RAY FILM-BLUE SENSITIVE POLYSTER BASE, DOUBLE EMULSION COATED	8" X 10"	Pkts of 50 nos	
63	CAT-VIII	X01002	X-RAY FILM-BLUE SENSITIVE POLYSTER BASE, DOUBLE EMULSION COATED	10" X 12"	Pkts of 50 nos	
64	CAT-VIII	X01003	X-RAY FILM-BLUE SENSITIVE POLYSTER BASE, DOUBLE EMULSION COATED	12" X 15"	Pkts of 50 nos	
65	CAT-VIII	X01006	X-RAY FILM-INTRA ORAL OCCLUSAL	SIZE-4(57X76mm)EKTA SPEED	Pks of 25 Films	
66	CAT-VIII	X01004	X-RAY FILM-INTRA ORAL PERIAPICAL	SIZE-2(31X41mm)EKTA SPEED IN POLY SOFT PACKET	Pks of 150 Films	
67	CAT-VIII	X01005	X-RAY FILM-INTRA ORAL PERIAPICAL	SIZE-0(22X35mm)EKTA SPEED IN POLY SOFT PACKET	Pks of 100 Films	
68	SPL	D13068	ACETYL SALICYLIC ACID + CLOPIDOGREL TAB	75mg + 75mg	1 no	
69	SPL	D09001	ACYCLOVIR IV INFUSION IP	250 mg	Vial	
70	SPL	D14045	ADAPALENE GEL BP	0.10%	15 gm	
71	SPL	D12030	ALTEPLASE INJ	50 mg	Vial	
72	SPL	D13067	AMBRISENTAN TAB IP	5 mg	1 no	
73	SPL	D08018	AMPHOTERICIN B LIPOSOMAL INJ	50mg	Vial	
74	SPL	D17064	ARIPIPRAZOLE TAB IP	10 mg	1 no	

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Offered Rate (Rs.)
75	SPL	D08031	ARTESUNATE +(SULPHADOXINE + PYREMETHAMINE)	Each Combi Blister Pack contains; [3 tablets of Artesunate (each 200mg) and 2 tablets of Sulphadoxine + Pyremethamine (each 750mg + 37.5mg)] OR [3 tablets of Artesunate (each 200mg) and 3 tablets of Sulphadoxine + Pyremethamine (each 500mg + 25mg)]	1 Blister Pack	
76	SPL	D08019	ARTESUNATE INJ IP	60mg	Vial	
77	SPL	D17045	ATOMOXETINE TAB	25mg	1 No	
78	SPL	D02099	AZTREONAM INJ USP	1 gm	Vial	
79	SPL	D22029	BENFOTIAMINE TAB	100 mg	1 NO	
80	SPL	D22030	BIOTIN TAB USP	5 mg	1 no	
81	SPL	D12031	BIVALIRUDIN INJ	250 mg	VIAL	
82	SPL	D29009	BOTULINUM TOXIN A INJ (FREEZE-DRIED POWDER FOR INJECTION)	50 Units	Vial	
83	SPL	D29008	BOTULINUM TOXIN A INJ (FREEZE-DRIED POWDER FOR INJECTION)	100 Units	Vial	
84	SPL	D03026	BUDESONIDE AND FORMOTEROL FUMARATE POWDER FOR INHALATION IP	100MCG + 6MCG Rotacap	1 no	
85	SPL	D03027	BUDESONIDE CONTROLLED RELEASE TAB	3 mg	1 No	
86	SPL	D17065	BUPROPION HCL TAB USP	150 mg	1 no	
87	SPL	D03028	CAFFEINE CITRATE INJ BP/USP	20mg/ml	3 ml Vial	
88	SPL	D15010	CHLORAMPHENICOL EYE APPLICAPS 1%	250MG	1.No	
89	SPL	D13072	CILNIDIPINE TAB IP	10 mg	1 No	
90	SPL	D29010	CITICOLINE INJ IP	500 mg	Amp	
91	SPL	D02102	CLINDAMYCIN GEL	1%	15 gm	
92	SPL	D14060	CLOBETASOL PROPIONATE + SALICYLIC ACID OINTMENT	0.05%w/w + **3.00**%w/w	20 gm tube	
93	SPL	D15068	CLOTRIMAZOLE+ ACETIC ACID EAR DROPS	1%w/v + 2%w/v	5ml	
94	SPL	D02104	CO-TRIMOXAZOLE INJ	Each ml contains Trimethoprim 16mg and Sulphamethoxazole 80mg	5 ml Vial	
95	SPL	D13074	DABIGATRAN TAB	110 mg	1 No	
96	SPL	D21046	DARIFENACIN TAB	7.5 mg	1 NO	

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Offered Rate (Rs.)
97	SPL	D14048	DESONIDE LOTION	0.05%	30 ml bottle	
98	SPL	D12033	DICUMAROL TAB	25mg	1 No	
99	SPL	D17062	DONEPEZIL TAB IP	10mg	1 No	
100	SPL	D03029	DOXOFYLLINE INJ	100 mg/10 ml	10 ml	
101	SPL	D02105	DOXYCYCLINE INJ	100 MG	Vial	
102	SPL	D21047	DUTASTERIDE CAP IP	0.5 mg	1 no	
103	SPL	D09008	ENTECAVIR TAB IP	0.5 MG	1 NO	
104	SPL	D29002	EPHEDRINE INJ BP	30mg/ml	1 ml amp	
105	SPL	D13077	ESMOLOL INJ IP	10 mg/ml	10 ml	
106	SPL	D16035	ESTRADIOL VALERATE TAB	2 MG	1no	
107	SPL	D12034	ETHAMSYLATE INJ	125mg/ml	2 ml	
108	SPL	D16028	ETHINYL OESTRADIOL AND CYPROTERONE ACETATE TAB	35 mcg+ 2mg	1 no	
109	SPL	D16014	ETHINYL OESTRADIOL AND DESOGESTREL TAB	20 mcg + 0.15mg	1 No	
110	SPL	D04032	ETOMIDATE INJ USP	2 mg/ml	10 ml	
111	SPL	D21048	FEBUXOSTAT TAB	40 mg	1 no	
112	SPL	D08023	FLUCONAZOLE INFUSION BP	200mg/100 ml	100 ml bottle	
113	SPL	D17066	FLUPENTHIXOL INJ IP	20 mg	Amp	
114	SPL	D14049	FLUTICASONE CREAM IP	0.05% W/W	15 gm	
115	SPL	D03030	FLUTICASONE FUROATE NASAL SPRAY	27.5 mcg	120 MD	
116	SPL	D07029	FOSPHENYTOIN INJ	Each ml contains; Fosphenytoin Sodium 75mg equivalent to Phenytoin Sodium 50mg	2ml Vial	
117	SPL	D14012	FRAMYCETIN SKIN CREAM	1% W/W	20 gm tube	
118	SPL	D14033	GENTAMICIN + CLOTRIMAZOLE + BECLOMETHASONE CREAM	0.1% + 1% + 0.025%	5gm tube	
119	SPL	D33001	GLUCOSAMINE TAB USP	500 mg	1 no	
120	SPL	D04033	GLYCOPYRROLATE TAB IP	1 MG	1 No	
121	SPL	D12032	HAEMOCOAGULASE INJ (ISOLATED FROM VENOM OF BOTHROPS ATOROX OR BOTHROPS JARARACA IN 0.9% W/V OF SODIUM CHLORIDE)	1 IU	1 ml amp	
122	SPL	D16029	HCG (HUMAN CHORIONIC GONADOTROPIN) INJ IP	5000 IU	Vial	
123	SPL	D16030	HMG (HUMAN MENOPAUSAL GONADOTROPIN) INJ	75 IU	Vial	
124	SPL	D12018	HUMAN ALBUMIN INJ IP	20%	100 ml	
125	SPL	D04025	HYALURONIDASE INJ IP	1500 IU	1 ml Vial	
126	SPL	D13078	HYDRALAZINE TAB BP	25 mg	1 no	
127	SPL	D13079	IBUTILIDE INJ	1mg/10ml	10 ml Vial	
128	SPL	D23007	IOHEXOL INJ	350mg/ml	100ml Bottle	
129	SPL	D13080	ISOPRENALINE INJ IP	2mg/ml	1 ml	

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Offered Rate (Rs.)
130	SPL	D14050	ISOTRETINOIN TAB	10mg	1 No	
131	SPL	D08040	ITRACONAZOLE TAB	200 mg	1 No	
132	SPL	D21020/12	IV GAMMAGLOBULIN INJ	5gm	Vial	
133	SPL	D13081	IVABRADINE TAB	5 mg	1 No	
134	SPL	D21050	L ORNITHINE L ASPARTATE INFUSION	5 gm/10ml	Amp	
135	SPL	D21051	L ORNITHINE L ASPARTATE POWDER	5 gm	Sachet	
136	SPL	D07030	LACOSAMIDE INJ	200 mg	vial	
137	SPL	D20043	LACTULOSE ENEMA	20% w/v	200 ml	
138	SPL	D09009	LAMIVUDINE TAB IP	100 MG	1 No	
139	SPL	D17068	LAMOTRIGINE TAB BP	50 mg	1 No	
140	SPL	D07027	LEVETIRACETAM INJ	100mg/ml	Amp	
141	SPL	D07017	LEVETIRACETAM SYRUP	100mg/ml	30 ml bottle	
142	SPL	D04034	LEVOBUPIVACAINE INJ	5 mg/ml	20ml vial	
143	SPL	D05027	LEVOCETIRIZINE TAB IP	5mg	1 No	
144	SPL	D13082	LEVOSIMENDAN INJ	2.5 MG/ML	5 ml Vial	
145	SPL	D20044	LEVOSULPIRIDE INJ	12.5 mg/ml	2ml	
146	SPL	D04027	LIGNOCAINE + PRILOCAINE CREAM IP	2.5% + 2.5%	30 gm tube	
147	SPL	D04036	LIGNOCAINE HYDROCHLORIDE TOPICAL SOLUTION (VISCOUS) IP	2%	100 ML BOTTLE	
148	SPL	D04035	LIGNOCAINE SPRAY	10%	50 ml BOTTLE	
149	SPL	D22031	MECOBALAMINE TAB	500mcg	1 No	
150	SPL	D02096	MEROPENAM INJ IP	1gm	Vial	
151	SPL	D20046	MESALAMINE TAB	800MG	1 No	
152	SPL	D19007	METOLAZONE TAB IP	5 mg	1 no	
153	SPL	D17030	MIRTAZAPINE TAB IP	15 mg	1 No	
154	SPL	D02107	MOXIFLOXACIN INJ FOR INTRACAMERAL USE BP	0.5 %w/v	0.5ml PFS	
155	SPL	D32001	MYCOPHENOLATE MOFETIL TAB IP	500 mg	1 No	
156	SPL	D14052	NADIFLOXACIN GEL IP	1%	10 gm tube	
157	SPL	D16032	NATURAL MICRONISED PROGESTERONE INJ	25 mg/ml	1ml	
158	SPL	D16031	NATURAL MICRONISED PROGESTERONE INJ	100mg/ml	1ml	
159	SPL	D13085	NIMODIPINE TAB BP	30 MG	1 No	
160	SPL	D20047	OCTREOTIDE INJ	100 mcg/ml	1 ml amp	
161	SPL	D13087	OLMESARTAN TAB IP	40 MG	1 No	
162	SPL	D21052	OXYBUTYNIN TAB BP	5 mg	1 no	
163	SPL	D20048	PANCRELIPASE DELAYED RELEASE CAP USP	Lipase-25000IU + Amylase-136000IU + Protease-85000IU (Dose by Lipase units)	1 NO	
164	SPL	D13088	PAPAVERINE HCL INJ BP	30 mg/ml	2ml	

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Offered Rate (Rs.)
165	SPL	D12036	PENTOXYFYLLINE TAB	400 mg	1 NO	
166	SPL	D15048	PERFLUORO-N-OCTANE LIQUID	Sterile ophthalmic preparation	5ml vial	
167	SPL	D15072	PILOCARPINE INJ FOR INTRACAMERAL USE	0.50%	1ml	
168	SPL	D14053	PODOPHYLLIN RESIN BP	25%	10ml bottle	
169	SPL	D20050	POLY ETHYLENE GLYCOL IP	117G	Sachet	
170	SPL	D15073	POTASSIUM IODIDE + SODIUM CHLORIDE + CALCIUM CHLORIDE + CARBOXY METHYL CELLULOSE EYE DROPS	3.30%	10 ML	
171	SPL	D15077	POVIDONE IODINE EYE DROPS BP	5%	5ml	
172	SPL	D16036	PROSTAGLANDIN E1 INJ	500 mcg	1 ml	
173	SPL	D13089	RANOLAZINE TAB	500 mg	1No	
174	SPL	D14054	RETINOIC ACID GEL	0.025%	10 gm tube	
175	SPL	D02109	RIFAXIMIN TAB	400 mg	1 no	
176	SPL	D04037	ROPIVACAINE INJ IP	0.5mg/ml	30ml	
177	SPL	D04028	SEVOFLURANE LIQUID	250 ml	Bottle	
178	SPL	D21053	SILDENAFIL INJ BP	10 mg	Vial	
179	SPL	D15054	SILICON OIL INJ	1000CST	10ml	
180	SPL	D21055	SILODOSIN CAP	8 mg	1 No	
181	SPL	D20052	SODIUM BICARBONATE TAB USP	500MG	1 No	
182	SPL	D15055	SODIUM CHLORIDE EYE OINTMENT BP	5%	5gm	
183	SPL	D20049	SODIUM PICOSULFATE TAB	10mg	1No	
184	SPL	D01015/12	SULFASALAZINE TAB	500mg	1No	
185	SPL	D03032	SURFACTANT (STERILE INTRATRACHEAL SUSPENSION) INJ	8 ml	Vial	
186	SPL	D32002	TACROLIMUS CAP IP	1 MG	1 NO	
187	SPL	D14056	TACROLIMUS OINTMENT	0.1%w/w	10 gm tube	
188	SPL	D21056	TAMSULOSIN + DUTASTERIDE CAP	0.4 mg + 0.5 mg	1 No	
189	SPL	D21057	TAMSULOSIN TAB	0.4 MG	1 No	
190	SPL	D02110	TEICOPLANINE INJ IP	400 mg	Vial	
191	SPL	D12037	TENECTEPLASE INJ	40 mg	Vial	
192	SPL	D21058	TENELIGLIPTIN TAB	20 MG	1 No	
193	SPL	D14057	TERBINAFINE CREAM IP	1%	10gm tube	
194	SPL	D14058	TERBINAFINE TAB IP	250 mg	1 no	
195	SPL	D13090	TERLIPRESSIN INJ	1mg/10ml	Vial	
196	SPL	D13091	TICAGRELOR TAB	90 MG	1 No	
197	SPL	D02111	TIGECYCLINE INJ	50 MG	Vial	
198	SPL	D12038	TIROFIBAN INJ	5mg/100ml	100 ml	
199	SPL	D01044	TOLPERISONE TAB	150mg	1 No	
200	SPL	D21059	TOLTERODINE TARTRATE TAB IP	2 mg	1 No	
201	SPL	D13092	TOLVAPTAN TAB	15 mg	1 No	

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Offered Rate (Rs.)
202	SPL	D19008	TORSEMIDE INJ	10 mg/ml	2ml Amp	
203	SPL	D19010	TORSEMIDE TAB IP	10 MG	1 No	
204	SPL	D19009	TORSEMIDE TAB IP	20 mg	1No	
205	SPL	D01054	TRAMADOL+ PARACETAMOL TAB	37.5mg+325mg	1 no	
206	SPL	D14059	TRETINOIN GEL USP	0.025%	15 GM tube	
207	SPL	D15075	TRYPAN BLUE FOR INTRACAMERAL INJ	0.06%w/v	1 ml, Glass Vial	
208	SPL	D17032	VENLAFAXINE TAB BP	75 mg	1 No	
209	SPL	D22034	VITAMIN D3 CAP	60000 IU	1 NO	
210	SPL	D22035	VITAMIN E CAP USP	400mg	1 no	
211	SPL	D15076	VORICONAZOLE EYE DROPS (LYOPHILIZED POWDER)	1%	3 ml VIAL	
212	SPL	D08042	VORICONAZOLE TAB IP	200 mg	1 No	
213	ACD	D24064C	CALCIUM LEUCOVERIN INJ	15mg	Vial	
214	ACD	D24065C	CALCIUM LEUCOVERIN INJ	50mg	Vial	
215	ACD	D24078C	DACARBAZINE INJ	200mg	Vial	
216	ACD	D24169C	DEXAMETHASONE TAB	4mg	1No	
217	ACD	D24090C	DOXORUBICIN LIPOSOMAL INJ	20mg	Vial	
218	ACD	D24097C	ETOPOSIDE INJ	100mg	Vial	
219	ACD	D24100C	FILGRASTIM INJ	300IU	Vial/PFS	
220	ACD	D24117C	L.ASPARGINASE INJ	5000iu	Vial	
221	ACD	D24163C	LENALIDOMIDE CAP	5mg	1No	
222	ACD	D24124C	MELPHALAN TAB	5mg	1No	
223	ACD	D24140C	PEGFILGRASTIM INJ	6mg	Vial/PFS	
224	ACD	D24145C	RITUXIMAB INJ	100mg	Vial	
225	ACD	D24146C	RITUXIMAB INJ	500mg	Vial	
226	ACD	D24059C	BENDAMUSTINE INJ	100mg	Vial	
227	ACD	D24162C	EVEROLIMUS TAB	5mg	1 No	
228	ACD	D24163C	LENALIDOMIDE CAP	5mg	1 No	
229	ACD	D24170C	ABIRATERONE TAB	250 mg	1 no	
230	ACD	D24171C	AFATINIB TAB	20 mg	1 no	
231	ACD	D24172C	AFATINIB TAB	30 mg	1 no	
232	ACD	D24173C	AFATINIB TAB	40 mg	1 no	
233	ACD	D24174C	AFATINIB TAB	50 mg	1 no	
234	ACD	D24057C	AMIFOSTINE INJ	500 mg	Vial	
235	ACD	D24175C	ANTI THYMOCYTE GLOBULIN INJ (EQUINE)	250 mg/5ml	Vial	
236	ACD	D24176C	ARSENIC TRIOXIDE INJ	10 mg	Vial	
237	ACD	D24177C	AXITINIB TAB	5 mg	1 no	
238	ACD	D24178C	AZACITIDINE INJ	100 mg	Vial	
239	ACD	D24168C	BETA-INTERFERON INJ	30 mcg	PFS	
240	ACD	D24179C	BUSULPHAN INJ	60 mg	Vial	
241	ACD	D24181C	CABAZITAXEL INJ	60 mg	Vial	
242	ACD	D24069C	CETUXIMAB INJ	100 mg	Vial	
243	ACD	D24073C	CLADRIBINE INJ	10 mg	Vial	
244	ACD	D24183C	CRIZOTINIB CAP	250 mg	1 no	

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Offered Rate (Rs.)
245	ACD	D24080C	DASATINIB TAB	50 mg	1 no	
246	ACD	D24185C	DECITABINE INJ	50 mg		
247	ACD	D24186C	DEGARELIX INJ	80 mg	Vial	
248	ACD	D24187C	DEGARELIX INJ	120 mg	Vial	
249	ACD	D24188C	DENOSUMAB INJ	120 mg	Vial	
250	ACD	D24089C	DOXORUBICIN (pegylated liposomal) INJ	10 mg	Vial	
251	ACD	D24091C	DOXORUBICIN (pegylated liposomal) INJ	50 mg	Vial	
252	ACD	D24189C	ELTROMBOPAG OLAMINE TAB	50 mg	1 no	
253	ACD	D24190C	ERIBULIN INJ	2 ml	Vial	
254	ACD	D24098C	EVEROLIMUS TAB	10 mg	1 no	
255	ACD	D24099C	EXEMESTANE TAB	25 mg	1 no	
256	ACD	D24191C	FLUDARABINE TAB	10 mg	1 no	
257	ACD	D24192C	FOSFESTROL TAB		1 no	
258	ACD	D24102C	FULVESTRANT INJ	250 mg	Vial	
259	ACD	D24106C	GOSERELIN INJ	3.6 mg	Vial	
260	ACD	D24107C	GOSERELIN INJ	10.8 mg	Vial	
261	ACD	D24193C	IDARUBICIN INJ	5 mg	Vial	
262	ACD	D24194C	INTERFERON ALFA INJ	3 MIU	PFS	
263	ACD	D24195C	L.ASPARAGINASE INJ	10000 IU	Vial	
264	ACD	D24118C	LAPATINIB TAB	250 mg	1 no	
265	ACD	D24122C	LEUPROLIDE ACETATE INJ	11.25 mg	Vial	
266	ACD	D24196C	MEGESTROL ACETATE TAB	40 mg	1 no	
267	ACD	D24197C	MELPHALAN INJ	50 mg	Vial	
268	ACD	D24198C	MERCAPTOPURINE TAB	50 mg	1 no	
269	ACD	D24199C	METHOTREXATE INJ	500 gm	Vial	
270	ACD	D24200C	METHOTREXATE INJ	1 gm	Vial	
271	ACD	D24201C	NILOTINIB CAP	200 mg	1 no	
272	ACD	D24202C	NIMOTUZUMAB INJ	200 mg	Vial	
273	ACD	D20047C	OCTREOTIDE INJ LA	10 mcg/ml	Vial	
274	ACD	D24132C	OCTREOTIDE INJ LA	30 mg	Vial	
275	ACD	D24204C	OCTREOTIDE INJ LA	20 mg	Vial	
276	ACD	D24205C	OCTREOTIDE INJ LA	10 mg	Vial	
277	ACD	D24206C	PANITUMUMAB INJ	100 mg	Vial	
278	ACD	D24207C	PAZOPANIB TAB	400 mg	1 no	
279	ACD	D24208C	PERTUZUMAB INJ	420 mg	Vial	
280	ACD	D24209C	POMALIDOMIDE CAP	2 mg	1 no	
281	ACD	D24210C	POMALIDOMIDE CAP	4 mg	1 no	
282	ACD	D24144C	PROTEIN BOUND PACLITAXEL INJ	100 mg	Vial	
283	ACD	D24211C	RASBURICASE INJ	1.5 mg	Vial	
284	ACD	D24212C	REGORAFENIB TAB	40 MG	1 no	
285	ACD	D24213C	RUXOLITINIB TAB	5 mg	1 no	
286	ACD	D24214C	RUXOLITINIB TAB	15 mg	1 no	
287	ACD	D24215C	RUXOLITINIB TAB	20 mg	1 no	

Sl No	Category	Drug Code	Drug Name	Strength	Unit	Offered Rate (Rs.)
288	ACD	D24216C	SUNITINIB CAP	12.5 mg	1 no	
289	ACD	D24148C	SUNITINIB CAP	25 mg	1 no	
290	ACD	D24217C	TEGAFUR +URACIL CAP	100mg + 224mg	1 no	
291	ACD	D24218C	TEMSIROLIMUS INJ		Vial	
292	ACD	D24155C	TOPOTECAN INJ	2.5 mg	Vial	
293	ACD	D24219C	TRABECTEDIN INJ	1 mg	Vial	
294	ACD	D24220C	TRASTUZUMAB EMTANSINE INJ	100 mg	Vial	
295	ACD	D24221C	TRASTUZUMAB EMTANSINE INJ	160 mg	Vial	
296	ACD	D24156C	TRASTUZUMAB INJ	440 mg	Vial	
297	ACD	D24222C	TRETINOIN CAP	10 mg	1 No	
298	ACD	D24159C	VINORELBINE INJ	50 mg	Vial	